FORM 6-K
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
Report of Foreign Issuer
 
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
 
For the month of April 2020
 
Commission File Number: 001-11960
 
AstraZeneca PLC
 
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F X Form 40-F __
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
 
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
 
Yes __ No X
 
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
 
 
 
 
 
AstraZeneca PLC
 
INDEX TO EXHIBITS
 
 
1.
AZN: first-quarter 2020 results
 
 
 
AstraZeneca PLC
29 April 2020 07:00 BST
 
First-quarter 2020 results
Robust results in unprecedented times; leveraging scientific expertise in the fight against COVID-19
 
AstraZeneca delivered a quarter of strong revenue and profit growth, reflecting the immense efforts of supply-chain, commercial and other colleagues around the world to get vital medicines to patients. As part of the fight, the Company has rapidly responded to the pandemic, firstly in China and then globally.
 
Pascal Soriot, Chief Executive Officer, commented:
"Our focus ensured another quarter of strong growth across every therapy area and region. The new medicines performed extremely well, and our pipeline continued to deliver. Standouts included landmark news for Tagrisso, Farxiga and Koselugo, our latest oncology medicine. The progress made on all fronts provides confidence that we will, once again, meet our full-year commitments.
 
I could not be prouder of how the AstraZeneca team has responded to the challenges of COVID-19. We moved quickly to maintain continuity of care, contribute to society, and use our scientific expertise to fight the pandemic. We hope our efforts to protect organs from damage, mitigate the cytokine storm and the associated hyperinflammatory state, and target the virus prove to be successful."
 
COVID-19
The Company donated nine million face masks to support healthcare workers around the world, delivered in collaboration with the World Economic Forum's COVID Action Platform. AstraZeneca also contributed to the UK Government's testing effort with a dedicated site in Cambridge operated in collaboration with the University of Cambridge and GlaxoSmithKline plc (GSK), with a goal to deliver 30,000 tests a day in May 2020.
 
The Company has mobilised research efforts to find new ways to help target the virus, reduce the cytokine storm, arising from an overactive immune response, and potentially protect organs. As part of the effort to target the virus, the Company is identifying novel SARS-CoV-2-neutralising monoclonal antibodies that can be used for treatment, as well as a prophylaxis against viral infection.
 
AstraZeneca is evaluating the use of Calquence, approved in a number of countries for the treatment of chronic lymphocytic leukaemia, in the Phase II CALAVI trial, which is assessing the suppression of the cytokine storm that inflames the lungs and other organs of some COVID-19 patients. The Company is also looking at protecting organs in the Phase III DARE-19 trial, assessing whether Farxiga, an oral medicine that has demonstrated benefits in heart failure and kidney disease, can potentially reduce organ failure. The Company has also joined the UK Government's ACCORD-2 proof-of-concept clinical-trial platform, to speed the development of medicines for patients with COVID-19.
 
Q1 2020 financial performance
 
Table 1: Financial summary
 
 
 
Q1 2020
 
$m
% change
Actual
CER1
Total Revenue
6,354
16
17
Product Sales
6,311
15
17
Collaboration Revenue
43
69
70
 
 
 
 
Reported2 EPS3
$0.59
27
33
Core4 EPS
$1.05
17
21
 
Of the growth at CER in Total Revenue, AstraZeneca estimates a low-to-mid single-digit percentage benefit of short-term inventory increases in the distribution channel, longer prescriptions and improved treatment-regimen adherence by patients, as indirect effects of the ongoing COVID-19 pandemic. This benefit is anticipated to reverse in the coming months.
 
The new medicines5 continued to perform especially well and there was excellent progress from the pipeline, with several regulatory approvals and particularly significant news regarding the potential use of Tagrisso in the adjuvant treatment of EGFRm6 lung cancer, as well as Farxiga in chronic kidney disease.
 
Total Revenue growth of 16% (17% at CER) to $6,354m; this included Product Sales of $6,311m (+15%, +17% at CER). Total Revenue increased in the quarter across all three therapy areas7 and in every region. Highlights included:
 
-     The performance of the new medicines, improving by 47% (49% at CER) to $2,986m, included new-medicine growth in Emerging Markets of 82% (87% at CER) to $658m. These medicines represented 47% of Total Revenue (Q1 2019: 37%)
 
-     Total Revenue growth across all therapy areas: Oncology +33% (+34% at CER) to $2,518m, New CVRM8 +7% (+8% at CER) to $1,102m and Respiratory & Immunology +21% (+22% at CER) to $1,555m
 
-     Total Revenue growth in every region: an increase in Emerging Markets of 13% (16% at CER) to $2,273m, with China Total Revenue growth of 14% (17% at CER) to $1,416m. Total Revenue in the US increased by 16% in the quarter to $2,091m and
       in Europe by 22% (25% at CER) to $1,204m; Japan Total Revenue increased by 10% (8% at CER) to $553m
 
Broad Company response to COVID-19
AstraZeneca's priority during the COVID-19 global pandemic is to continue to safely supply all of the Company's medicines to millions of patients. A description of the specific impact on and the actions by the Company regarding the pandemic is shown below; for the latest AstraZeneca communications regarding COVID-19, please click here.
 
a)   Colleagues
Office-based colleagues are typically working from home; in a growing number of countries that are potentially past the pandemic's peak, however, colleagues have returned to the office, in line with government guidelines. For supply-chain and research and development (R&D) roles that cannot be performed from home, AstraZeneca has put clear processes in place relating to social distancing. In April 2020, the Company implemented voluntary assessments of critical supply-chain and manufacturing colleagues at three sites, using the Company's own laboratories, to rapidly identify and isolate COVID-19 cases.
 
b)   Supply chain
The Company did not see any material disruptions to its supply chain in the period. AstraZeneca's manufacturing sites in China returned to full capacity within weeks of the declared outbreak, with little intervening impact on supply. The Company's supply chain includes an effective inventory management policy for each medicine, as well as robust business continuity plans (BCPs). These plans seek to ensure that there are appropriate inventory levels of active pharmaceutical ingredients and critical materials to ensure manufacturing and supply continuity. AstraZeneca's approach to BCP utilises various strategic measures, for example, inventory, dual-supply processes, and operational agility.
 
Some medicines experienced particular growth in global demand in the quarter, partly reflecting short-term inventory increases in the distribution channel, as well as prescription-lengthening and improved treatment-regimen adherence by patients. This growth in the quarter was within the Company's fulfilment capability; AstraZeneca is, however, closely monitoring fulfilment risks, particularly within Respiratory & Immunology.
 
c)   Sales and marketing
Interactions with healthcare professionals and organisations have been significantly impacted and virtual meetings today, especially in the US, Europe and Japan, remain predominant. As part of the early response to the pandemic, AstraZeneca quickly expanded its levels of digital activities, including:
 
-     remote detailing to healthcare professionals
 
-     collaborating with telemedicine providers and e-pharmacies
 
-     investing in new platforms designed for communication with healthcare professionals
 
In a growing number of countries that are potentially past the pandemic's peak, face-to-face meetings with healthcare professionals have been increasingly reinitiated.
 
d)   Clinical trials
AstraZeneca has focused on ensuring the continued safety of patients in all of its ongoing clinical trials, while activating continuity plans in order to minimise trial disruption from the pandemic. Mitigation strategies included home-based treatment and monitoring options, moving patient recruitment to less-affected regions, and planning for accelerated recruitment once the pandemic has receded. Having assessed the COVID-19 impact across the pipeline, the Company does not expect material delays to anticipated dates of late-stage and lifecycle-management news flow in 2020 and 2021.
 
Impact on operations, performance and the Condensed Consolidated Interim Financial Statements
The impact of COVID-19 on the Company's operations is highly uncertain and cannot be predicted with confidence and the extent of any adverse impact on AstraZeneca's operations will depend on the global duration, extent and severity of the pandemic. To the extent the pandemic adversely affects AstraZeneca operations and/or performance, the Company expects it to have the effect of heightening many of the risks described beginning on page 246 in the Risk section of the Annual Report and Form 20-F Information 2019, such as those relating to the delivery of the pipeline or launch of new medicines, the execution of the Company's commercial strategy, the manufacturing and supply of medicines and reliance on third-party goods and services.
 
In the current environment, the Directors have considered the impact of a range of possible future COVID-19 related scenarios and believe the Group retains sufficient liquidity to continue to operate. As detailed in Note 1 of the Notes to the Interim Financial Statements, the going-concern basis has been adopted in these Condensed Consolidated Interim Financial Statements (Interim Financial Statements). For an impact assessment on the Interim Financial Statements, also see Note 1.
 
Guidance
The Company provides guidance for FY 2020 at CER on:
 
-     Total Revenue, comprising Product Sales and Collaboration Revenue
 
-     Core EPS
 
Guidance on Total Revenue and Core EPS reflects the changing nature and growing strategic impact of Collaboration Revenue which, over time, will primarily comprise potential income from existing collaborations as follows:
 
-      A share of gross profits derived from sales of Enhertu in several markets, where those sales are recorded by Daiichi Sankyo Company, Limited (Daiichi Sankyo)
-      A share of gross profits derived from sales of roxadustat in China, recorded by FibroGen Inc. (FibroGen)9
-      Milestone revenue from the MSD10 collaboration on Lynparza
-      Smaller amounts of milestone and royalty revenue from other marketed and pipeline medicines
 
The guidance below is subject to the assumption that the global impact of the COVID-19 pandemic lasts for several more months and is based on recent trends in the business. The Company will monitor closely the development of the pandemic and anticipates providing an update at the H1 2020 results. Variations in performance between quarters can be expected to continue.
 
 

 
Financial guidance for FY 2020 is unchanged. Total Revenue is expected to increase by a high single-digit to a low double-digit percentage and Core EPS is expected to increase by a mid- to high-teens percentage. AstraZeneca recognises the heightened risks and uncertainties from the impact of COVID-19 referred to above.
 

 
The Company is unable to provide guidance and indications on a Reported basis because the Company cannot reliably forecast material elements of the Reported result, including any fair-value adjustments arising on acquisition-related liabilities, intangible asset impairment charges and legal-settlement provisions. Please refer to the section cautionary statements regarding forward-looking statements at the end of this announcement.
 
Indications
The Company provides indications for FY 2020 at CER:
 
-     The Company is focused on improving operating leverage
 
-     A Core Tax Rate of 18-22%. Variations in the Core Tax Rate between quarters are anticipated to continue
 
-     Capital Expenditure is expected to be broadly stable versus the prior year
 
Currency impact
If foreign-exchange rates for April to December 2020 were to remain at the average of rates seen in the quarter, it is anticipated that there would be a low single-digit adverse impact on Total Revenue and Core EPS. In addition, the Company's foreign-exchange rate sensitivity analysis is contained within the operating and financial review.
 
Financial summary
-     Total Revenue, comprising Product Sales and Collaboration Revenue, increased by 16% in the quarter (17% at CER) to $6,354m. Product Sales increased by 15% (17% at CER) to $6,311m, primarily driven by the performance of the new medicines, as well as Symbicort's double-digit growth at CER in every region
 
-     The Reported and Core Gross Profit Margin11 declined by two percentage points in the quarter to 77% and 78% respectively. The falls reflected the impact of one-off adjustments related to Group inventory, the growth in profit share from the collaboration with MSD in respect of Lynparza and an element of foreign-exchange impact
 
-     Reported Total Operating Expense increased by 9% in the quarter (10% at CER) to $4,194m and represented 66% of Total Revenue (Q1 2019: 70%); part of the rise, also reflected in Core R&D Expense, was driven by the investment related to Enhertu. Core Total Operating Expense increased by 7% (8% at CER) to $3,600m and represented 57% of Total Revenue (Q1 2019: 61%); the increase was also driven by SG&A Expense related to investment in Oncology-medicine launches and AstraZeneca's further expansion in China. In addition, Reported SG&A Expense was adversely impacted by intangible asset impairments, including a $102m charge relating to Bydureon
 
-     The Reported Operating Profit Margin declined in the quarter by one percentage point (stable at CER) to 19%; the Core Operating Profit Margin also declined by one percentage point (stable at CER) to 29%
 
-     Reported EPS of $0.59 in the quarter, represented an increase of 27% (33% at CER); this was despite an increase in the weighted-average number of shares to 1,312m (Q1 2019: 1,267m). Core EPS increased by 17% (21% at CER) to $1.05
 
Commercial summary
 
Oncology
Total Revenue increased by 33% in the quarter (34% at CER) to $2,518m.
 
Table 2: Select Oncology medicine performances
 
 
 
Q1 2020
 
$m
% change
Actual
CER
Tagrisso: Product Sales
982
56
58
Imfinzi: Product Sales
462
57
57
Lynparza: Product Sales
397
67
69
Calquence: Product Sales
88
n/m12
n/m
Enhertu: Collaboration Revenue
14
n/m
n/m
 
Oncology Total Revenue increased in Emerging Markets by 45% (49% at CER) to $711m.
 
New CVRM
Total Revenue increased by 7% in the quarter (8% at CER) to $1,102m.
 
Table 3: Select New CVRM medicine performances
 
 
 
Q1 2020
 
$m
% change
Actual
CER
Farxiga: Total Revenue
407
16
19
Brilinta: Product Sales
408
17
19
Bydureon: Product Sales
100
(30)
(29)
Lokelma: Product Sales
11
n/m
n/m
Roxadustat: Collaboration Revenue
3
n/m
n/m
 
New CVRM Total Revenue increased in Emerging Markets by 39% in the quarter (43% at CER) to $332m.
 
Respiratory & Immunology
Total Revenue increased by 21% in the quarter (22% at CER) to $1,555m.
 
Table 4: Select Respiratory & Immunology medicine performances
 
 
 
Q1 2020
 
$m
% change
Actual
CER
Symbicort: Product Sales
790
35
36
Pulmicort: Product Sales
380
(1)
-
Fasenra: Product Sales
199
54
55
 
Respiratory & Immunology Total Revenue increased in Emerging Markets by 4% (6% at CER) to $540m.
 
Following the launch of an authorised-generic version of Symbicort in the US in collaboration with Prasco, LLC (Prasco), US sales of Symbicort grew by 76% in the quarter to $310m. The performance partly reflected an element of inventory build by Prasco.
 
Emerging Markets
As the Company's largest region, at 36% of Total Revenue, Emerging Markets' Total Revenue increased by 13% in the quarter (16% at CER) to $2,273m, including:
 
-     A China Total Revenue increase of 14% (17% at CER) to $1,416m
 
-     An ex-China Total Revenue increase of 12% (15% at CER) to $857m
 
Sustainability summary
Recent developments and progress against the Company's sustainability priorities are reported below:
 
-     Access to healthcare: during the period, AstraZeneca announced a donation of nine million face masks to support healthcare workers around the world as they respond to the COVID-19 global pandemic; more than eight million masks have already been delivered. In addition, AstraZeneca, GSK and the University of Cambridge announced a collaboration to support the UK Government's five-pillar plan to boost testing
 
-     Environmental protection: to coincide with Earth Day on 22 April 2020, the Company announced a new one-year collaboration focusing on water stewardship with World Wide Fund for Nature Sweden, to identify opportunities to improve the Company's approach and strategy towards water stewardship. AstraZeneca's longer-term ambition is to implement Science-Based Targets for Water, once a global methodology is available, to lead the way on water stewardship for the pharmaceutical industry; including the development of industry-specific tools to assess water risk in the context of Pharmaceuticals in the Environment
 
-     Ethics and transparency: since committing to providing greater transparency around payments to healthcare professionals and healthcare organisations at the 2018 Annual General Meeting, the Company has further progressed this work during the period across Canada, the Philippines and New Zealand, while continuing to monitor the regulatory landscape in Argentina, Chile, India and Morocco
 
A more extensive sustainability update is provided later in this announcement.
 
Notes
The following notes refer to pages one to six.
 
1.    Constant exchange rates. These are financial measures that are not accounted for according to generally accepted accounting principles (GAAP) because they remove the effects of currency movements from Reported results.
 
2.    Reported financial measures are the financial results presented in accordance with International Financial Reporting Standards (IFRS), as issued by the International Accounting Standards Board and adopted by the EU. The UK is yet to announce its IFRS endorsement authority and is anticipated to continue to follow the EU endorsement process for the foreseeable future.
 
3.    Earnings per share.
 
4.    Core financial measures. These are non-GAAP financial measures because, unlike Reported performance, they cannot be derived directly from the information in the Group's Interim Financial Statements. See the operating and financial review for a definition of Core financial measures and a reconciliation of Core to Reported financial measures.
 
5.   Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Farxiga, Brilinta, Lokelma, roxadustat, Fasenra, Bevespi and Breztri. The new medicines are pillars in the three therapy areas and are important platforms for future growth. The Total Revenue of Enhertu and roxadustat in the quarter entirely reflected Ongoing Collaboration Revenue.
 
6.    Epidermal growth factor receptor mutation.
 
7.    Defined here as Oncology, New CVRM and Respiratory & Immunology.
 
8.     New Cardiovascular (CV), Renal & Metabolism comprises Brilinta and Renal & Diabetes medicines.
 
9.   FibroGen and AstraZeneca are collaborating on the development and commercialisation of roxadustat in the US, China, and other global markets. FibroGen and Astellas Pharma Inc. (Astellas) are collaborating on the development and commercialisation of roxadustat in territories including Japan, Europe, the Commonwealth of Independent States, the Middle East and South Africa.
 
10.  Merck & Co., Inc., Kenilworth, NJ, US, known as MSD outside the US and Canada.
 
11.  Gross Profit is defined as Total Revenue minus Cost of Sales. The calculation of Reported and Core Gross Margin excludes the impact of Collaboration Revenue and any associated costs, thereby reflecting the underlying performance of Product Sales.
 
12.  Not meaningful.
 
Table 5: Pipeline highlights
 
The following table highlights significant developments in the late-stage pipeline since the prior results announcement:
 
 
Regulatory approvals
-     Imfinzi - ES[11]-SCLC[12] (US)
-     Enhertu - breast cancer (3rd line[13], HER2+[14]) (JP)
-     Koselugo (selumetinib) - NF1[15] (US)
-     Lokelma - hyperkalaemia (JP)
 
Regulatory submission acceptances and/or submissions
-     Lynparza - prostate cancer (2nd line): regulatory submission (JP)
-     Koselugo - NF1: regulatory submission acceptance (EU)
 
Major Phase III data readouts or other significant developments
-     Tagrisso - adjuvant NSCLC[16] (EGFRm): unblinded for overwhelming efficacy
-     Imfinzi - ES-SCLC: OS[17] confirmed
-     Imfinzi + treme - ES-SCLC: primary endpoint not met
-     Imfinzi +/- treme - bladder cancer (1st line[18]): primary endpoints not met
-     Lynparza - prostate cancer: secondary OS endpoint met
-     Lynparza - pancreatic cancer: orphan designation (JP)
-     cediranib - ovarian cancer (2nd line[19]): primary endpoint not met
-     Farxiga - CKD[20]: primary endpoint met early
 
 
Table 6: Pipeline - anticipated major news flow
Innovation is critical to addressing unmet patient needs and is at the heart of the Company's growth strategy. The focus on research and development is designed to yield strong and sustainable results from the pipeline.
 
 
Timing
 
News flow
 
Q2 2020
 
-     Imfinzi - ES-SCLC: regulatory submission (CN)
-     Lynparza - ovarian cancer (1st line) (PAOLA-1): regulatory decision (US)
-     Lynparza - breast cancer (BRCAm[21]): regulatory decision (CN)
-     Lynparza - prostate cancer (2nd line): regulatory decision (US)
-     Enhertu - gastric cancer (3rd line, HER2+): regulatory submission
 
-     Forxiga - T2D[22] CVOT[23]: regulatory decision (CN)
-     Farxiga - HF[24] CVOT: regulatory decision (US)
 
-     Symbicort - mild asthma: regulatory submission (EU)
-     Bevespi - COPD[25]: regulatory decision (CN)
 
H2 2020
 
-     Tagrisso - adjuvant NSCLC (EGFRm): regulatory submission
-     Imfinzi - unresectable[26], Stage III NSCLC (PACIFIC-2): data readout
-     Imfinzi - ES-SCLC: regulatory decision (EU, JP)
-     Imfinzi +/- treme - liver cancer (1st line): data readout
-     Lynparza - ovarian cancer (1st line) (PAOLA-1): regulatory decision (EU)
-     Lynparza - ovarian cancer (3rd line, BRCAm): regulatory submission (US)
-     Lynparza - pancreatic cancer (1st line, BRCAm): regulatory decision (EU)
-     Lynparza - prostate cancer (2nd line): regulatory decision (EU)
-     Enhertu - breast cancer (3rd line, HER2+): regulatory submission (EU)
-     Calquence - CLL[27]: regulatory decision (EU)
 
-     Forxiga - HF CVOT: regulatory decision (EU, JP, CN)
-     Farxiga - CKD: regulatory submission
-     Brilinta/Brilique - CAD[28]/T2D CVOT: regulatory decision (US, EU)
-     roxadustat - anaemia in CKD: regulatory decision (US)
 
-     Symbicort - mild asthma: regulatory decision (CN)
-     Fasenra - nasal polyposis[29]: data readout
-     PT010 - COPD: regulatory decision (US, EU)
-     PT027 - asthma: data readout
-     tezepelumab - severe asthma: data readout
-     anifrolumab - lupus (SLE[30]): regulatory submission
 
2021
-     Imfinzi - unresectable, Stage III NSCLC (PACIFIC-2): regulatory submission
-     Imfinzi - adjuvant NSCLC: data readout, regulatory submission
-     Imfinzi - liver cancer (locoregional): data readout, regulatory submission
-     Imfinzi +/- treme - NSCLC (1st line) (POSEIDON): data readout (OS), regulatory submission
-     Imfinzi +/- treme - liver cancer (1st line): regulatory submission
-     Imfinzi +/- treme - head & neck cancer (1st line): data readout, regulatory submission
-     Lynparza - adjuvant breast cancer: data readout, regulatory submission
-     Lynparza - prostate cancer (2nd line): regulatory decision (JP)
-     Lynparza - prostate cancer (1st line, castration-resistant): data readout, regulatory submission
-     Enhertu - breast cancer (2nd line, HER2+): data readout, regulatory submission
-     Enhertu - breast cancer (3rd line, HER2+) (Phase III): data readout
-     Enhertu - breast cancer (HER2-low[31]): data readout
-     Calquence - CLL: regulatory decision (JP)
-     Koselugo - NF1: regulatory decision (EU)
 
-     roxadustat - anaemia in myelodysplastic syndrome[32]: data readout
 
-     Fasenra - nasal polyposis: regulatory submission
-     PT027 - asthma: regulatory submission
-     tezepelumab - severe asthma: regulatory submission
 
Conference call
A conference call and webcast for investors and analysts will begin at 11:45am UK time today. Details can be accessed via astrazeneca.com.
 
Report calendar
The Company intends to publish its first-half and second-quarter financial results on 30 July 2020.
 
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, CVRM and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
 
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
 
 
Operating and financial review

 
All narrative on growth and results in this section is based on actual exchange rates, and financial figures are in US$ millions ($m), unless stated otherwise. The performance shown in this announcement covers the three-month period to 31 March 2020 (the quarter or Q1 2020) compared to the three-month period to 31 March 2019 (Q1 2019) respectively, unless stated otherwise.
 
Core financial measures, EBITDA, Net Debt, Initial Collaboration Revenue and Ongoing Collaboration Revenue are non-GAAP financial measures because they cannot be derived directly from the Group's Interim Financial Statements. Management believes that these non-GAAP financial measures, when provided in combination with Reported results, will provide investors and analysts with helpful supplementary information to understand better the financial performance and position of the Group on a comparable basis from period to period. These non-GAAP financial measures are not a substitute for, or superior to, financial measures prepared in accordance with GAAP. Core financial measures are adjusted to exclude certain significant items, such as:
 
-     Amortisation and impairment of intangible assets, including impairment reversals but excluding any charges relating to IT assets
 
-     Charges and provisions related to restructuring programmes, which includes charges that relate to the impact of restructuring programmes on capitalised IT assets
 
-     Other specified items, principally comprising acquisition-related costs, which include fair-value adjustments and the imputed finance charge relating to contingent consideration on business combinations and legal settlements
 
Details on the nature of Core financial measures are provided on page 80 of the Annual Report and Form 20-F Information 2019. Reference should be made to the Reconciliation of Reported to Core financial measures table included in the financial performance section of this announcement.
 
EBITDA is defined as Reported Profit Before Tax after adding back Net Finance Expense, results from Joint Ventures and Associates and charges for Depreciation, Amortisation and Impairment. Reference should be made to the Reconciliation of Reported Profit Before Tax to EBITDA included in the financial performance section of this announcement.
 
Net Debt is defined as interest-bearing loans and borrowings and lease liabilities, net of cash and cash equivalents, other investments, and net derivative financial instruments. Reference should be made to Note 3 'Net Debt' included in the Notes to the Interim Financial Statements in this announcement.
 
Ongoing Collaboration Revenue is defined as Collaboration Revenue excluding Initial Collaboration Revenue (which is defined as Collaboration Revenue that is recognised at the date of completion of an agreement or transaction, in respect of upfront consideration). Ongoing Collaboration Revenue comprises, among other items, royalties, milestone revenue and profit-sharing income. Reference should be made to the Collaboration Revenue table in this operating and financial review.
 
The Company strongly encourages investors and analysts not to rely on any single financial measure, but to review AstraZeneca's financial statements, including the Notes thereto and other available Company reports, carefully and in their entirety.
 
Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
 
Table 7: Total Revenue by therapy area
 
 
 
Q1 2020
 
$m
 
% change
% of total
Actual
CER
Oncology
2,518
40
33
34
BioPharmaceuticals
2,657
42
15
16
New CVRM
1,102
17
7
8
Respiratory & Immunology
1,555
24
21
22
Other medicines
1,179
19
(8)
(6)
 
 
 
 
 
Total
6,354
100
16
17
 
Specialty-care medicines comprise all Oncology medicines, Brilinta, Lokelma, roxadustat and Fasenra. At 49% of Total Revenue (Q1 2019: 43%), specialty-care medicine Total Revenue increased by 32% in the quarter (34% at CER) to $3,139m.
 
Table 8: Top-ten medicines by Total Revenue
 
 
Medicine
Therapy Area
Q1 2020
 
$m
% of total
% change
Actual
CER
Tagrisso
Oncology
982
15
56
58
Symbicort
Respiratory
790
12
35
36
Imfinzi
Oncology
462
7
57
57
Brilinta
CVRM
408
6
17
19
Farxiga
CVRM
407
6
16
19
Lynparza
Oncology
397
6
67
69
Pulmicort
Respiratory
380
6
(1)
-
Nexium
Other medicines
348
5
(6)
(5)
Crestor
CVRM
302
5
(10)
(8)
Zoladex
Oncology
228
4
16
19
 
 
 
 
 
 
Total
 
4,704
74
26
28
 
Table 9: Collaboration Revenue
 
 
 
Q1 2020
 
$m
% of total
% change
Actual
CER
Enhertu: profit share
14
33
n/m
n/m
Roxadustat: profit share
3
7
n/m
n/m
Other Ongoing Collaboration Revenue
26
60
4
5
 
 
 
 
 
Total
43
100
69
70
 
Other Ongoing Collaboration Revenue included Zoladex, Farxiga, Nexium OTC and other royalties. No Initial Collaboration Revenue was recorded in the quarter.
 
 
Total Revenue

 
The performance of the Company's medicines is shown below, with a geographical split of Product Sales shown in Note 7.
 
Table 10: Therapy area and medicine performance
 
 
Therapy area
Medicine
Q1 2020
 
$m
% of total
% change
Actual
CER
Product Sales: Oncology
Tagrisso
982
16
56
58
Imfinzi
462
7
57
57
Lynparza
397
6
67
69
Calquence
88
1
n/m
n/m
Zoladex
225
4
16
19
Faslodex
166
3
(35)
(34)
Iressa
77
1
(42)
(41)
Arimidex
50
1
(1)
1
Casodex
42
1
(12)
(10)
Others
13
-
(37)
(36)
Total Oncology
2,502
40
32
34
Product Sales: BioPharmaceuticals - CVRM
Farxiga
405
6
16
19
Brilinta
408
6
17
19
Bydureon
100
2
(30)
(29)
Onglyza
141
2
(8)
(6)
Byetta
20
-
(32)
(31)
Other diabetes
13
-
16
18
Lokelma
11
-
n/m
n/m
Crestor
301
5
(10)
(9)
Seloken/Toprol-XL
177
3
(21)
(18)
Atacand
66
1
33
36
Others
59
1
(18)
(17)
BioPharmaceuticals: total CVRM
1,701
27
(1)
1
Product Sales: BioPharmaceuticals - Respiratory & Immunology
Symbicort
790
13
35
36
Pulmicort
380
6
(1)
-
Fasenra
199
3
54
55
Daliresp/Daxas
53
1
11
12
Bevespi
12
-
22
22
Breztri
4
-
n/m
n/m
Others
113
2
(11)
(10)
BioPharmaceuticals: total Respiratory & Immunology
1,551
25
21
22
Product Sales: other medicines
Nexium
338
5
(7)
(6)
Synagis
85
1
61
61
Losec/Prilosec
54
1
(30)
(28)
Seroquel XR/IR
36
1
(4)
(3)
Others
44
1
(8)
(7)
Total other medicines
557
9
(4)
(3)
 
Total Product Sales
6,311
100
15
17
 
 
 
 
 
 
Total Collaboration Revenue
43
 
69
70
 
 
 
 
 
Total Revenue
6,354
 
16
17
 
 
Total Revenue summary

 
Oncology
Total Revenue of $2,518m in the quarter; an increase of 33% (34% at CER). No Lynparza Collaboration Revenue was recorded in this quarter. The performance of Enhertu was reflected in Collaboration Revenue; no Product Sales of Enhertu were recorded in the quarter.
 
Oncology Total Revenue represented 40% of overall Total Revenue (Q1 2019: 35%).
 
Tagrisso
Tagrisso has received regulatory approval in 81 countries, including the US, China, in the EU and Japan for the 1st-line treatment of patients with EGFRm NSCLC. To date, reimbursement has been granted in 20 countries, with further reimbursement decisions anticipated throughout 2020, as well as additional regulatory decisions in many countries. This followed Tagrisso's approval and launch in 88 countries, including the US, China, in the EU and Japan for the treatment of patients with EGFR T790M[33]-mutated NSCLC.
 
Total Revenue, entirely comprising Product Sales, amounted to $982m in the quarter and represented growth of 56% (58% at CER). This was partly driven by the aforementioned regulatory approvals and reimbursements in the 1st-line setting. Continued growth was also delivered in the 2nd-line setting, for example, within Europe and Emerging Markets. Sequentially, Total Revenue increased by $98m from Q4 2019 to Q1 2020, including sequential growth in the US. Total Revenue in the US increased by 43% year-on-year in the quarter to $371m. Demand growth continued, with Tagrisso established as the standard of care (SoC) in the 1st-line setting, following regulatory approval in 2018.
 
In Emerging Markets, Tagrisso Total Revenue increased by 103% in the quarter (109% at CER) to $280m, with notable growth in China, following the admission in 2019 to the China National Drug Reimbursement List (NRDL) in the 2nd-line setting. Tagrisso Total Revenue in Japan increased by 25% (23% at CER) to $153m. In Europe, Total Revenue of $162m in the quarter represented an increase of 62% (66% at CER), driven by its emerging use in the 1st-line setting, as more reimbursements were granted, as well as continued strong levels of demand in the 2nd-line setting.
 
Imfinzi
Imfinzi has received regulatory approval in 62 countries, including the US, China, in the EU and Japan for the treatment of patients with unresectable, Stage III NSCLC whose disease has not progressed following platinum-based chemoradiation therapy (CRT). The number of reimbursement agreements increased to 27 in the quarter. During the period, Imfinzi was also approved for the treatment of ES-SCLC patients in the US and Singapore. It is also approved for the 2nd-line treatment of patients with locally advanced or metastatic urothelial carcinoma (bladder cancer) in 16 countries, including in the US.
 
Total Revenue, entirely comprising Product Sales, amounted to $462m in the quarter and represented growth of 57%, almost exclusively for the treatment of unresectable, Stage III NSCLC. Total Revenue in the US increased by 24% to $286m. In Japan, growth of 66% (64% at CER) represented sales of $56m. Sales in Europe of $75m followed recent regulatory approvals and launches. Imfinzi was also launched in the quarter in China for the treatment of unresectable, Stage III NSCLC.
 
Lynparza
Lynparza has received regulatory approval in 73 countries for the treatment of ovarian cancer. Launches for the treatment of metastatic breast cancer took place in the US and Japan in 2018 in the EU in April 2019. Lynparza has now been approved in 64 countries for the treatment of metastatic breast cancer and, in four countries, including the US, for the treatment of pancreatic cancer.
 
Total Revenue amounted to $397m in the quarter and represented growth of 67% (69% at CER); no Lynparza Collaboration Revenue was recorded in the period. The strong performance was geographically spread, with launches continuing in Emerging Markets and the Established Rest of World region (RoW).
 
US sales amounted to $197m and increased by 66%, driven by the launch in the 1st-line BRCAm ovarian cancer setting at the end of 2018. Lynparza continued to be the leading medicine in the poly ADP ribose polymerase-inhibitor class, as measured by total prescription volumes in both ovarian and breast cancer. Sales in Europe increased by 57% (61% at CER) to $102m, driven by increasing levels of reimbursement and BRCAm-testing rates, as well as successful recent 1st-line ovarian cancer launches, including in the UK and Germany.
 
Japan sales of Lynparza amounted to $34m, representing growth of 55% (53% at CER). Emerging Markets sales of $56m, up by 113% (120% at CER), reflected the regulatory approval of Lynparza as a 2nd-line maintenance treatment of patients with ovarian cancer by the China National Medical Products Administration (NMPA). Lynparza was admitted to the China NRDL for the same indication, with effect from January 2020.
 
Calquence
Total Revenue, entirely comprising Product Sales, amounted to $88m in the quarter and represented growth of 202%, with the overwhelming majority of sales in the US. Calquence was approved by the US Food and Drug Administration (FDA) for the treatment of CLL and small lymphocytic lymphoma (SLL) in November 2019. Calquence has received 13 regulatory approvals for the treatment of patients with mantle-cell lymphoma, and six in CLL.
 
Enhertu
Product Sales, recorded by Daiichi Sankyo, amounted to $30m. This reflected sales in the US, where Enhertu has been launched and where Daiichi Sankyo is the principal. Total Revenue, entirely comprising resulting Collaboration Revenue recorded by AstraZeneca, amounted to $14m in the quarter, following the recent launch in the US at the beginning of the year. Enhertu was approved by the US FDA for the treatment of 3rd-line HER2+ breast cancer in December 2019.
 
Legacy: Iressa
Total Revenue, entirely comprising Product Sales, amounted to $77m in the quarter and represented a decline of 42% (41% at CER). Sales in Emerging Markets declined by 28% (26% at CER) to $62m, reflecting Iressa's inclusion on the China volume-based procurement programme.
 
Legacy: Faslodex
Total Revenue, entirely comprising Product Sales, amounted to $166m in the quarter and represented a decline of 35% (34% at CER).
 
Emerging Markets sales of Faslodex increased by 7% (10% at CER) to $48m. US sales declined by 83% to $23m, reflecting the launch of multiple generic Faslodex medicines. In Europe, where generic competitor medicines are established, sales increased by 19% (22% at CER) to $64m, while in Japan, sales increased by 4% (3% at CER) to $29m.
 
Legacy: Zoladex
Total Revenue, predominantly comprising Product Sales, amounted to $228m in the quarter and represented growth of 16% (19% at CER).
 
Emerging Markets sales of Zoladex increased by 30% (35% at CER) to $149m. Sales in Europe increased by 1% (3% at CER) to $35m. In the Established RoW region, sales declined by 10% (9% at CER) to $39m, driven by the effects of increased competition.
 
 
BioPharmaceuticals: CVRM
Total Revenue, which included roxadustat Ongoing Collaboration Revenue of $3m and sales of Crestor and other legacy medicines, were stable in the quarter (increase of 1% at CER) to $1,707m and represented 27% of Total Revenue (Q1 2019: 31%).
 
New CVRM Total Revenue, which excluded sales of Crestor and other legacy medicines, increased by 7% in the quarter (8% at CER) to $1,102m, reflecting strong performances from Farxiga and Brilinta. New CVRM Total Revenue represented 17% of overall Total Revenue in the quarter (Q1 2019: 19%); this change partly reflected the particular growth of Oncology.
 
Farxiga
Total Revenue, predominantly comprising Product Sales, amounted to $407m in the quarter and represented growth of 16% (19% at CER).
 
Emerging Markets sales increased by 49% (55% at CER) to $141m. In China, Farxiga was admitted to the NRDL with effect from the start of 2020; as expected, this adversely impacted the price of the medicine. This impact, however, was offset by the volume benefit derived from the launch within the NRDL listing. The performance also reflected growth in the sodium-glucose layer transport protein 2 (SGLT2) inhibitor class at the expense of the dipeptidyl-peptidase 4 (DPP-4) inhibitor class.
 
US sales declined by 14% to $113m. Growth in the quarter was adversely affected by the impact on price from increased levels of competition, the mix of sales and managed markets. There were, however, favourable movements in the share of new-to-brand prescriptions, a result of a label update in Q3 2019 to reflect results from the DECLARE CVOT.
 
Sales in Europe increased by 30% (34% at CER) to $116m, partly reflecting growth in the SGLT2 inhibitor class and an acceleration of new-to-brand prescriptions following a similar DECLARE label update. In Japan, sales to the collaborator, Ono Pharmaceutical Co., Ltd, which records in-market sales, declined by 24% (25% at CER) to $13m.
 
Brilinta
Total Revenue, entirely comprising Product Sales, amounted to $408m in the quarter and represented growth of 17% (19% at CER). Patient uptake continued in the treatment of acute coronary syndrome and high-risk post-myocardial infarction (MI); the performance also reflected aforementioned short-term inventory increases, given the hospital-dispensation setting.
 
Emerging Markets sales of Brilinta increased by 38% (42% at CER) to $134m. US sales of Brilinta, at $165m, represented an increase of 8%, driven primarily by increasing levels of demand in both hospital and retail settings, as well as a lengthening in the average-weighted duration of treatment, reflecting the growing impact of 90-day prescriptions. Sales of Brilique in Europe increased by 12% in the quarter (15% at CER) to $93m, reflecting performances in Spain, Germany and the UK.
 
Onglyza
Total Revenue, entirely comprising Product Sales, amounted to $141m in the quarter and represented a decline of 8% (6% at CER).
 
Sales in Emerging Markets increased by 10% (13% at CER) to $47m, driven by the performance in China. US sales of Onglyza declined by 14% in the quarter to $67m; given the significant future potential of Farxiga, the Company continues to prioritise commercial support over Onglyza. Europe sales declined by 19% (17% at CER) to $15m, also highlighting the broader trend of a shift away from the DPP-4 inhibitor class.
 
Bydureon
Total Revenue, entirely comprising Product Sales, amounted to $100m in the quarter and represented a decline of 30% (29% at CER).
 
US sales of $84m reflected a decline of 28% in the quarter, resulting from competitive pressures and the impact of managed markets. Patients continue to transition from the dual-chamber pen to the BCise device. Bydureon sales in Europe fell by 34% (32% at CER) to $12m. Reflecting the recent and potential performance of Bydureon, a $102m intangible asset impairment charge was recorded in the quarter.
 
Lokelma
Total Revenue, entirely comprising Product Sales, amounted to $11m in the quarter and reflected sequential growth of 42% over Q4 2019.
 
The US represented the overwhelming majority of sales, following the recent launch of the medicine. Lokelma led new-to-brand prescription market share during the quarter. The medicine has received regulatory approval in the EU, China and Japan and for the treatment of hyperkalaemia, with further launches in several markets anticipated soon.
 
Roxadustat
Total Revenue, entirely comprising Ongoing Collaboration Revenue, amounted to $3m in the quarter. The period saw a focus on achieving hospital listings across the country. Roxadustat was approved by the China NMPA for the treatment of anaemia in CKD in dialysis-dependent and non-dialysis dependent patients in December 2018 and August 2019, respectively. Roxadustat was admitted to the China NRDL with effect from January 2020.
 
Legacy: Crestor
Total Revenue, predominantly comprising Product Sales, amounted to $302m in the quarter and represented a decline of 10% (8% at CER).
 
Sales in Emerging Markets declined by 15% (13% at CER) to $192m. The performance was adversely impacted by the effect of volume-based procurement in China. US sales increased by 9% to $28m. In Europe, sales declined by 12% (10% at CER) to $34m. In Japan, where AstraZeneca collaborates with Shionogi Co. Ltd, sales increased by 5% (3% at CER) to $34m.
 
 
BioPharmaceuticals: Respiratory & Immunology
Total Revenue, which included Ongoing Collaboration Revenue of $3m from Duaklir and Eklira, increased by 21% in the quarter (22% at CER) to $1,555m and represented 24% of Total Revenue (Q1 2019: 23%).
 
Symbicort
Total Revenue, entirely comprising Product Sales, amounted to $790m in the quarter and represented growth of 35% (36% at CER).
 
An authorised-generic version of Symbicort was launched in the US by the Company's collaborator, Prasco. US sales grew by 76% to $310m; this partly reflected an element of inventory build by Prasco. Symbicort also continued its global market-volume and value leadership within the inhaled corticosteroid / long-acting beta agonist (LABA) class. Emerging Markets sales increased by 17% in the quarter (20% at CER) to $156m, reflecting particularly strong performances in China and the Middle East & Africa.
 
In Europe, sales increased by 7% in the quarter (10% at CER) to $195m. In Japan, sales grew by 40% (38% at CER) to $56m, supported by the continued effect of AstraZeneca regaining full rights, following termination in 2019 of the Astellas co-promotion agreement. In Japan, Symbicort pricing was, however, adversely impacted by the recent market entry of a generic medicine.
 
Pulmicort
Total Revenue, entirely comprising Product Sales, amounted to $380m in the quarter and represented a decline of 1% (stable at CER).
 
Emerging Markets, where sales were stable in the quarter (+1% at CER) at $313m, represented 82% of global Total Revenue of Pulmicort. The performance in China was impacted by local COVID-19 pandemic restrictions, resulting in a disruption of hospital dispensation and significantly reduced access and attendance to outpatient nebulisation rooms. It also reflected a particularly benign influenza season in China, resulting in a significantly reduced number of asthma exacerbations. Sales in the US declined by 3% to $23m and sales in Europe increased by 3% (6% at CER) to $26m.
 
Fasenra
Fasenra has received regulatory approval in 56 countries, including in the US, the EU and Japan for the treatment of patients with severe, uncontrolled eosinophilic asthma. With further regulatory reviews ongoing, Fasenra has already achieved reimbursement in 39 countries. Total Revenue, entirely comprising Product Sales, amounted to $199m in the quarter and represented growth of 54% (55% at CER).
 
Sales in the US increased by 29% in the quarter to $120m. For the aforementioned treatment of patients, Fasenra ended the quarter as the leading novel biologic medicine in the US, as measured by new-to-brand prescriptions. In Europe, sales of $46m in the quarter represented an increase of 154% (161% at CER), reflecting a number of successful launches. Sales in Japan increased by 32% (30% at CER) to $21m. In its approved indication and among new patients, Fasenra obtained the leading market share of all biologic medicines in the 'top-five' European countries and in Japan. In Emerging Markets, sales amounted to $6m in the quarter (Q1 2019: $nil).
 
Daliresp/Daxas
Total Revenue, entirely comprising Product Sales, amounted to $53m in the quarter and represented growth of 11% (12% at CER).
 
US sales, representing 85% of the global total, increased by 10% to $45m, driven by higher demand, partially offset by adverse inventory movements.
 
Bevespi
Total Revenue, entirely comprising Product Sales, amounted to $12m in the quarter and represented growth of 22%.
 
Bevespi has been launched in the US, in a number of European countries and in Japan. The global LABA / long acting muscarinic antagonist class continued to grow more slowly than expected.
 
Breztri
Total Revenue, entirely comprising Product Sales, amounted to $4m in the quarter (Q1 2019: $nil).
 
Following regulatory approvals for the treatment of COPD, Breztri was launched in Japan and China.
 
 
Other medicines (outside the three main therapy areas)
Total Revenue, primarily comprising Product Sales, amounted to $557m in the quarter; a decline of 4% (3% at CER). Other Total Revenue represented 9% of overall Total Revenue (Q1 2019: 10%).
 
Nexium
Total Revenue, predominantly comprising Product Sales, amounted to $348m in the quarter; a decline of 6% (5% at CER). Emerging Markets sales of Nexium declined by 2% (an increase of 1% at CER) to $187m. In Japan, where AstraZeneca collaborates with Daiichi Sankyo, sales were stable at $79m.
 
 
Regional Total Revenue

 
Table 11: Regional Total Revenue
 
 
 
Q1 2020
 
$m
% of total
% change
Actual
CER
Emerging Markets
2,273
36
13
16
China
1,416
22
14
17
Ex-China
857
14
12
15
 
 
 
 
 
US
2,091
33
16
16
 
 
 
 
 
Europe
1,204
19
22
25
 
 
 
 
 
Established RoW
786
12
13
13
Japan
553
9
10
8
Canada
156
2
37
36
Other Established RoW
77
1
(1)
5
 
 
 
 
 
Total
6,354
100
16
17
 
Table 12: Emerging Markets therapy-area performance
 
 
 
Q1 2020
 
$m
% of total
% change
Actual
CER
Oncology
711
31
45
49
BioPharmaceuticals
872
38
15
18
New CVRM
332
15
39
43
Respiratory & Immunology
540
24
4
6
Other medicines
690
30
(9)
(7)
 
 
 
 
 
Total
2,273
100
13
16
 
Table 13: Notable new-medicine performances in Emerging Markets - Total Revenue
 
 
 
Q1 2020
 
$m
% change
Actual
CER
Tagrisso
280
n/m
n/m
Forxiga
142
49
55
Brilinta
134
38
42
Lynparza
55
n/m
n/m
Imfinzi
33
n/m
n/m
 
The new medicines represented 29% of Emerging Markets Total Revenue (Q1 2019: 18%). Total Revenue from specialty-care medicines increased by 45% (50% at CER) to $854m and comprised 38% of Emerging Markets sales in the quarter (Q1 2019: 29%).
 
China Total Revenue, which included $3m of roxadustat Ongoing Collaboration Revenue, comprised 62% of Emerging Markets Total Revenue in the quarter and increased by 14% (17% at CER) to $1,416m.
 
New-medicine Total Revenue in China, primarily driven by Tagrisso and Lynparza in Oncology and Brilinta and Farxiga in New CVRM, delivered particularly encouraging growth and represented 27% of China Total Revenue (Q1 2019: 13%). This performance was augmented by strong sales of Zoladex, Symbicort and a resilient performance from Pulmicort.
 
Ex-China Emerging Markets, comprising entirely of Product Sales, increased by 12% in the quarter (15% at CER) to $857m. The new medicines represented 32% of ex-China Emerging Markets Total Revenue in the quarter (Q1 2019: 26%), increasing by 41% (45% at CER) to $277m. The performance was underpinned by strong levels of growth across the following:
 
Table 14: Ex-China Emerging Markets: Total Revenue
 
 
 
Q1 2020
 
$m
% change
Actual
CER
Russia
84
72
66
Brazil
89
(5)
6
Ex-Brazil Latin America
108
7
18
Ex-China Asia Pacific
311
11
12
Middle East and Africa
265
11
12
 
 
Financial performance

 
Table 15: Reported Profit and Loss
 
 
 
Q1 2020
Q1 2019
% change
$m
$m
Actual
CER
Total Revenue
6,354
5,491
16
17
                                                              Product Sales
6,311
5,465
15
17
                                                             Collaboration Revenue
43
26
69
70
 
 
 
 
 
Cost of Sales
(1,420)
(1,129)
26
26
 
 
 
 
 
Gross Profit
4,934
4,362
13
15
Gross Margin
77.5%
79.3%
(2)
(2)
 
 
 
 
 
Distribution Expense
(87)
(78)
11
13
% Total Revenue
1.4%
1.4%
-
-
R&D Expense
(1,388)
(1,266)
10
10
% Total Revenue
21.8%
23.1%
1
2
SG&A Expense
(2,719)
(2,514)
8
9
% Total Revenue
42.8%
45.8%
3
3
 
 
 
 
 
Other Operating Income & Expense
480
593
(19)
(19)
% Total Revenue
7.6%
10.8%
(3)
(3)
 
 
 
 
 
Operating Profit
1,220
1,097
11
16
Operating Profit Margin
19.2%
20.0%
(1)
-
 
 
 
 
 
Net Finance Expense
(281)
(312)
(10)
(9)
Joint Ventures and Associates
(4)
(27)
(85)
(85)
 
 
 
 
 
Profit Before Tax
935
758
23
29
 
 
 
 
 
Taxation
(185)
(195)
(5)
(1)
Tax Rate
20%
26%
 
 
   
 
 
 
Profit After Tax
750
563
33
40
 
 
 
 
 
EPS
0.59
0.47
27
33
 
 
Table 16: Reconciliation of Reported Profit Before Tax to EBITDA
 
 
 
Q1 2020
Q1 2019
% change
$m
$m
Actual
CER
Reported Profit Before Tax
935
758
23
29
Net Finance Expense
281
312
(10)
(9)
Joint Ventures and Associates
4
27
(85)
(85)
Depreciation, Amortisation and Impairment
841
676
24
26
 
 
 
 
 
EBITDA
2,061
1,773
16
20
 
Table 17: Reconciliation of Reported to Core financial measures
 
 
Q1 2020
Reported
Restructuring
Intangible Asset Amortisation & Impairments
Diabetes Alliance
Other
Core
Core % change
$m
$m
$m
$m
$m
$m
Actual
CER
Gross Profit
4,934
19
17
-
5
4,975
12
14
Gross Profit Margin
77.5%
 
 
 
 
78.1%
-2
-2
 
 
 
 
 
 
 
 
 
Distribution Expense
(87)
-
-
-
-
(87)
11
13
R&D Expense
(1,388)
11
42
-
(1)
(1,336)
9
9
SG&A Expense
(2,719)
25
449
67
1
(2,177)
5
7
Total Operating Expense
(4,194)
36
491
67
-
(3,600)
7
8
 
 
 
 
 
 
 
 
 
Other Operating Income & Expense
480
(2)
1
-
-
479
(19)
(19)
 
 
 
 
 
 
 
 
 
Operating Profit
1,220
53
509
67
5
1,854
12
16
Operating Profit Margin
19.2%
 
 
 
 
29.2%
-1
-
 
 
 
 
 
 
 
 
 
Net Finance Expense
(281)
-
-
57
55
(169)
(11)
(11)
Taxation
(185)
(11)
(107)
(31)
-
(334)
1
5
 
 
 
 
 
 
 
 
 
EPS
$0.59
$0.03
$0.31
$0.07
$0.05
$1.05
17
21
 
 
Profit and Loss summary
 
 
a)    Gross Profit
The increases in Reported and Core Gross Profit in the quarter reflected the growth in Product Sales. The declines in the Reported and Core Gross Margin partly reflected the impact of one-off adjustments related to Group inventory, the growth in profit share from the collaboration with MSD in respect of Lynparza and an element of foreign-exchange impact.
 
b)   Total Operating Expense
Reported Total Operating Expense in the quarter represented 66% of Total Revenue (Q1 2019: 70%), Core Total Operating Expense represented 57% of Total Revenue (Q1 2019: 61%).
 
Reported and Core R&D Expense increased partly as a result of investment in the development of Enhertu. Reported and Core SG&A Expense grew primarily due to additional select investment in Oncology-medicine launches and AstraZeneca's further expansion in China. In addition, Reported SG&A Expense was adversely impacted by an increased level of intangible asset impairments, including a $102m charge relating to Bydureon.
 
c)   Other Operating Income and Expense[34]
Reported and Core Other Operating Income and Expense in the quarter included $350m of income that reflected an agreement to divest commercial rights to a number of legacy hypertension medicines.
 
d)   Net Finance Expense
The declines in Reported and Core Net Finance Expense partly reflected a favourable movement in loan interest following the repayment of a $1bn bond in 2019.
 
e)   Taxation
The Reported and Core Tax Rates for the quarter were both 20% (Q1 2019: 26% and 23% respectively). Taxation Paid for the quarter was $477m, representing 51% of Reported Profit Before Tax (Q1 2019: $334m, 44%).
 
f)    EPS
Reported EPS of $0.59 in the quarter, represented an increase of 27% (33% at CER). This was despite an increase in the weighted-average number of shares to 1,312m (Q1 2019: 1,267m). Core EPS increased by 17% (21% at CER) to $1.05.
 
Table 18: Cash Flow
 
 
 
Q1 2020
Q1 2019
Change
$m
$m
$m
Reported Operating Profit
1,220
1,097
123
Depreciation, Amortisation and Impairment
841
676
165
 
 
 
 
Increase in Working Capital and Short-Term Provisions
(445)
(710)
265
Gains on Disposal of Intangible Assets
(358)
(512)
154
Non-Cash and Other Movements
(462)
(396)
(66)
Interest Paid
(180)
(208)
28
Taxation Paid
(477)
(334)
(143)
 
 
 
 
Net Cash Inflow/(Outflow) from Operating Activities
139
(387)
526
Net Cash Inflow/(Outflow) before Financing Activities
148
(59)
207
Net Cash Outflow from Financing Activities
(2,362)
(698)
(1,664)
 
The increase in Net Cash Inflows from Operating Activities in the quarter primarily reflected an underlying improvement in business performance, combined with favourable working-capital movements. The positive cash performance was partly offset by the aforementioned increase in Taxation Paid.
 
The increase in Net Cash Inflows before Financing Activities primarily reflected the aforementioned improvement in Net Cash Inflows from Operating Activities, as well as a reduction in the Purchase of Intangible Assets, partially offset by a reduction in cash flows from the Disposal of Intangible Assets. The cash payment of contingent consideration, in respect of the former Bristol-Myers Squibb Company (BMS) share of the global diabetes alliance, amounted to $124m in the quarter.
 
Capital Expenditure
Capital expenditure amounted to $186m in the quarter, compared to $174m in Q1 2019. This included investment in the new AstraZeneca R&D centre on the Biomedical Campus in Cambridge, UK.
 
The Company anticipates a broadly stable level of total capital expenditure in FY 2020 (FY 2019: $979m).
 
Table 19: Net Debt summary
 
 
 
At 31
Mar 2020
At 31
Dec 2019
At 31
Mar 2019
$m
$m
$m
Cash and Cash Equivalents
3,413
5,369
4,136
Other Investments
804
911
876
 
 
 
 
Cash and Investments
4,217
6,280
5,012
 
 
 
 
Overdrafts and Short-Term Borrowings
(691)
(225)
(2,044)
Lease Liabilities
(653)
(675)
(714)
Current Instalments of Loans
(1,598)
(1,597)
(1,500)
Loans Due After One Year
(15,634)
(15,730)
(17,320)
 
 
 
 
Interest-Bearing Loans and Borrowings (Gross Debt)
(18,576)
(18,227)
(21,578)
 
 
 
 
Net Derivatives
(54)
43
295
Net Debt
(14,413)
(11,904)
(16,271)
 
Capital allocation
The Board's aim is to continue to strike a balance between the interests of the business, financial creditors and the Company's shareholders. After providing for investment in the business, supporting the progressive dividend policy and maintaining a strong, investment-grade credit rating, the Board will keep under review potential investment in immediately earnings-accretive, value-enhancing opportunities.
 
Foreign exchange
The Company's transactional currency exposures on working-capital balances, which typically extend for up to three months, are hedged where practicable using forward foreign-exchange contracts against the individual companies' reporting currency. Foreign-exchange gains and losses on forward contracts for transactional hedging are taken to profit or loss. In addition, the Company's external dividend payments, paid principally in pounds sterling and Swedish krona, are fully hedged from announcement to payment date.
 
Table 20: Currency sensitivities
The Company provides the following currency-sensitivity information:
 
 
 
Average Exchange
Rates versus USD
 
Annual Impact of 5% Strengthening in Exchange Rate versus USD ($m)[35]
Currency
Primary Relevance
FY 2019[36]
Q1 2020[37]
% change
Product Sales
Core Operating Profit
CNY
Product Sales
6.92
6.99
(1)
288
190
EUR
Product Sales
0.89
0.91
(1)
171
68
JPY
Product Sales
108.98
108.91
-
139
98
Other[38]
 
 
 
 
231
123
 
 
 
 
 
 
 
GBP
Operating Expense
0.78
0.78
-
27
(93)
SEK
Operating Expense
9.46
9.67
(2)
5
(51)
 
 
Sustainability

 
AstraZeneca's sustainability approach has three priority areas[39], aligned with the Company's purpose and business strategy:
 
-     Access to healthcare
 
-     Environmental protection
 
-     Ethics and transparency
 
Recent developments and progress against the Company's priorities are reported below:
 
a)   Access to healthcare
During the period, AstraZeneca announced a donation of nine million face masks to support healthcare workers around the world as they respond to the COVID-19 global pandemic. The Company has also collaborated with the World Economic Forum's COVID Action Platform, created with the support of the World Health Organization, to identify countries in greatest need; more than eight million masks have already been delivered.
 
During the period, AstraZeneca proactively communicated with its healthcare and community partners, who are working to support healthcare systems, patients and caregivers around the world, to reinforce the Company's support of their efforts during the COVID-19 pandemic. AstraZeneca will continue to meet funding commitments and support community partner decisions to postpone or cancel programmes or reallocate funding towards relief and response efforts. For example, Healthy Heart Africa (HHA) collaborators who support the delivery of the Company's programme in local communities in Kenya, Ethiopia, Tanzania and Ghana, have repurposed local facilities and diverted resources towards providing protective clothing to healthcare workers. AstraZeneca's Young Health Programme partners have stopped all community-based outreach and are delivering disease prevention messaging over virtual networks. In addition, the Company is ensuring that its collaborators are safe and supported and is encouraging them to follow the appropriate governmental guidance.
 
In March 2020, the manuscript 'Burden of prehypertension among adults in Kenya: a retrospective analysis of findings from the HHA programme' was published in the BMC Public Health journal; this was the third HHA manuscript published in the last twelve months. The publication outlined the high prevalence of hypertension (HTN) and pre-HTN in Kenya, with more than 50% of the six million screening records analysed found to have pre-HTN, in addition to 20% with HTN, among an average screening age of 45 years.
 
b)   Environmental protection
To coincide with Earth Day on 22 April 2020, AstraZeneca announced a new one-year collaboration focusing on water stewardship with World Wide Fund for Nature Sweden, to identify opportunities to improve the Company's approach and strategy towards water stewardship. Responsible management of water, particularly where sites are situated in water-stressed areas, is critical to the development and manufacture of the Company's medicines. AstraZeneca's longer-term ambition is to implement Science-Based Targets for Water, once a global methodology is available, to lead the way on water stewardship for the pharmaceutical industry; including the development of industry-specific tools to assess water risk in the context of Pharmaceuticals in the Environment.
 
This approach will ensure that AstraZeneca is more meaningfully contributing to the sustainable management of water resources within river basins. The Company's water target is to maintain absolute water use at the 2015 level through 2025. Since 2015, the Company has developed a standard methodology to assess water risk and stress at its global sites, which has enabled the Company to broaden its understanding of water-related risks and opportunities for priority investment. AstraZeneca has prioritised implementing water-efficiency projects, identified through water audits at 11 sites, including Yelahanka, Bangalore, India; Shanghai, China; and Canóvanas, Puerto Rico; and implemented rainwater harvesting at five sites: Wuxi, China; Cambridge, UK; Macclesfield, UK; Canóvanas, Puerto Rico and Frederick, US.
 
During the period, the AstraZeneca Green Labs initiative received two 'My Green Lab' certifications, reflecting the Company's commitment to laboratory sustainability. AstraZeneca's R&D site in Boston, US achieved Gold Level Certification for implementing over 60% of recommended sustainable lab practices; and the Company's R&D site in South San Francisco, US achieved Green Level Certification, awarded for implementing over 80% of recommended-sustainability practices. This is the highest level of certification provided by My Green Lab, placing the Company's South San Francisco site as one of only 10 laboratories certified at this level, out of more than 400 worldwide. The programme is the first of its scope in the industry, bringing together scientists, facilities management, engineering and safety health and environment to improve the environmental sustainability of research laboratories. AstraZeneca's major sites in the UK and Sweden are in scope and aim to become My Green Lab certified in the coming months.
 
c)   Ethics and transparency
Since committing to providing greater transparency around payments to healthcare professionals and healthcare organisations at the 2018 Annual General Meeting, AstraZeneca successfully progressed in 2019 the disclosure programme into an additional five markets covering Brazil, Colombia, Korea, Mexico and Saudi Arabia. In 2020, the Company is intending to further progress this work across Canada, the Philippines (where enhanced legislation has been recently passed, superseding the existing Administrative Order) and New Zealand, while continuing to monitor the regulatory landscape in Argentina, Chile, India and Morocco.
 
d)   Other developments
In March 2020, the Company released its sixth annual Sustainability Report via its website and social media. The report was released in conjunction with the Annual Report and Form 20-F Information 2019. The report outlined progress and challenges and aims for the future. Many of the new sustainability initiatives and programmes launched in 2019 were a result of engagement and activism from AstraZeneca colleagues around the world, demonstrating how sustainability is being embedded across the organisation.
 
 
 

For more details on AstraZeneca's sustainability ambition, approach and targets, please refer to the latest Sustainability Report 2019 and Sustainability Data Summary 2019. Additional information is available at astrazeneca.com/sustainability.
 

 
 
Research and development

 
As the COVID-19 pandemic develops, the Company will evaluate the impact on the initiation of clinical trials, ongoing recruitment and follow-ups. It is prudent to assume that some delays will arise as a consequence of the pandemic. AstraZeneca does not expect significant delays to anticipated late-stage and lifecycle-management 2020 and 2021 news-flow dates.
 
A comprehensive data pack comprising AstraZeneca's pipeline of medicines in human trials can be found in the latest clinical-trials appendix, available on astrazeneca.com. Highlights of developments in the Company's late-stage pipeline since the prior results announcement are shown below:
 
Table 21: Update from the late-stage pipeline
 
 
New molecular entities and major lifecycle events for medicines in Phase III trials or under regulatory review
17
Oncology
 
-     Tagrisso - NSCLC
-     Imfinzi - multiple cancers
-     Lynparza - multiple cancers
-     Enhertu - breast and other cancers
-     capivasertib - breast cancer
-     Calquence - blood cancers
-     tremelimumab - multiple cancers
-     savolitinib - NSCLC[40]
 
 
CVRM
-     Farxiga - multiple indications
-     roxadustat - anaemia in CKD
 
 
Respiratory & Immunology
-     Fasenra - multiple indications
-     Breztri - asthma
-     PT027 - asthma
-     tezepelumab - severe asthma
-     nirsevimab - respiratory syncytial virus
-     anifrolumab - lupus (SLE)
-     brazikumab[41] - inflammatory bowel disease
Total projects
in clinical pipeline
 
167
 
 
Oncology
 
Oncology: lung cancer
 
a)   Tagrisso
 
In April 2020, the Company announced that the ADAURA Phase III trial for Tagrisso in the adjuvant treatment of patients with Stage IB, II and IIIA EGFRm NSCLC with complete tumour resection was to be unblinded early following a recommendation from an Independent Data Monitoring Committee (IDMC), based on its determination of overwhelming efficacy. The primary endpoint of the trial is disease-free survival. Tagrisso was assessed against placebo for a treatment duration of up to three years. The trial will continue to assess the secondary endpoint of OS. In its communication to AstraZeneca, the IDMC did not raise any new safety concerns. The data will be presented at a forthcoming medical meeting.
 
Table 22: Key Tagrisso trials in lung cancer
 
 
Trial
Population
Design
Timeline
Status
Phase III
ADAURA
Adjuvant EGFRm NSCLC
Placebo or Tagrisso
FPCD[42]
Q4 2015
 
LPCD[43]
Q1 2019
Trial unblinded early due to overwhelming efficacy
Phase III
LAURA
Locally advanced, unresectable EGFRm NSCLC
Placebo or Tagrisso
FPCD
Q4 2018
 
First data anticipated
2021+
Recruitment
ongoing
Phase III
FLAURA2
1st-line EGFRm NSCLC
Tagrisso or Tagrisso + platinum-based chemotherapy doublet
FPCD
Q4 2019
 
First data anticipated
2021+
Recruitment ongoing
 
b)    Imfinzi
In March 2020, the Company announced that Imfinzi had been approved in the US as a 1st-line treatment for adult patients with ES-SCLC in combination with SoC chemotherapies, etoposide plus either carboplatin or cisplatin (platinum-etoposide) utilising the fixed dose of Imfinzi 1,500mg every three weeks, for four cycles with chemotherapy, then every four weeks until progression. This followed the regulatory approval in Singapore earlier in the period.
 
Prior to this, AstraZeneca announced high-level results from the final analysis of the Phase III CASPIAN trial, which showed that Imfinzi, in combination with a choice of SoC chemotherapies, confirmed a sustained, clinically meaningful OS benefit for patients with ES-SCLC treated in the 1st-line setting. The second experimental arm, testing tremelimumab, an anti-CTLA4 monoclonal antibody, added to Imfinzi and SoC, did not meet its primary endpoint of demonstrating a statistically significant improvement in OS. In June 2019, it was announced that the CASPIAN trial met one primary endpoint for Imfinzi plus SoC by demonstrating a statistically significant and clinically meaningful improvement in OS versus SoC alone at a planned interim analysis.
 
During the period, AstraZeneca announced that the Phase III DANUBE trial for Imfinzi and Imfinzi plus tremelimumab in unresectable, Stage IV (metastatic) bladder cancer did not meet the primary endpoints of improving OS versus SoC chemotherapy for Imfinzi monotherapy in patients whose tumour cells and/or tumour-infiltrating immune cells express high levels (≥25%) of PD-L1[44], or for Imfinzi plus tremelimumab in patients regardless of their PD-L1 expression. The safety and tolerability profiles for Imfinzi and the combination with tremelimumab were consistent with previous trials. The data will be presented at a forthcoming medical meeting.
 
Table 23: Key Imfinzi trials in lung cancer
 
 
Trial
Population
Design
Timeline
Status
Phase III
AEGEAN
Neo-adjuvant (before surgery) NSCLC
SoC chemotherapy +/- Imfinzi,
followed by
surgery, followed by placebo or Imfinzi
FPCD
Q1 2019
 
First data anticipated
2021+
Recruitment
ongoing
Phase III
ADJUVANT BR.31[45]
Stage Ib-IIIa NSCLC
Placebo or
Imfinzi
FPCD
Q1 2015
 
LPCD
Q1 2020
 
First data anticipated
2021
Recruitment
completed
Phase III
PACIFIC-2
Stage III unresected locally advanced NSCLC
(concurrent CRT)
Placebo or
Imfinzi
FPCD
Q2 2018
 
LPCD
Q3 2019
 
First data anticipated
H2 2020
Recruitment
completed
Phase III
ADRIATIC
Limited-
stage SCLC
Concurrent CRT,
followed by
placebo or
Imfinzi or Imfinzi + treme
FPCD
Q4 2018
 
First data anticipated
2021+
Recruitment
ongoing
Phase III
POSEIDON
Stage IV, 1st-line NSCLC
SoC chemotherapy or SoC + Imfinzi or SoC + Imfinzi + treme
FPCD
Q2 2017
 
LPCD
Q4 2018
 
OS data anticipated
2021
PFS[46] primary endpoint met
Phase III
CASPIAN
ES-SCLC
SoC chemotherapy or SoC + Imfinzi or SoC + Imfinzi + treme
FPCD
Q1 2017
 
LPCD
Q2 2018
OS primary endpoint met for Imfinzi monotherapy arm
 
OS primary endpoint not met for Imfinzi + treme
 
During the period, the AEGEAN trial in neo-adjuvant NSCLC was expanded to include 800 patients and the primary endpoints optimised to include event-free survival, as well as major pathological response. The first data are now anticipated beyond 2021.
 
As previously announced, the POSEIDON trial of Imfinzi and chemotherapy trial with and without tremelimumab in 1st-line NSCLC will continue to assess the additional primary endpoint of OS, following the positive PFS readout in 2019, with data anticipated in 2021. The Company anticipates presenting the trial outcomes at a forthcoming medical meeting when the overall trial outcomes are obtained.
 
Table 24: Key Imfinzi trials in tumour types other than lung cancer
 
 
Trial
Population
Design
Timeline
Status
Phase III
POTOMAC
Non-muscle invasive bladder cancer
SoC BCG[47] or SoC BCG + Imfinzi
FPCD
Q4 2018
 
First data
anticipated
2021+
Recruitment ongoing
Phase III
NIAGARA
Muscle-invasive bladder cancer
Neo-adjuvant cisplatin and gemcitabine SoC chemotherapy or SoC + Imfinzi, followed by adjuvant placebo or Imfinzi
FPCD
Q4 2018
 
First data
anticipated
2021+
Recruitment ongoing
Phase III
EMERALD-1
Locoregional HCC[48]
TACE[49] followed by placebo or TACE + Imfinzi, followed by Imfinzi +
bevacizumab or
TACE + Imfinzi
followed by Imfinzi
FPCD
Q1 2019
 
First data
anticipated
2021
Recruitment ongoing
Phase III
EMERALD-2
Locoregional HCC at high risk of recurrence after surgery or radiofrequency ablation
Adjuvant Imfinzi or Imfinzi + bevacizumab
FPCD
Q2 2019
 
First data anticipated
2021+
Recruitment ongoing
Phase III
CALLA
Locally advanced cervical cancer
CRT or CRT + Imfinzi, followed by placebo or Imfinzi
FPCD
Q1 2019
 
First data anticipated
2021+
Recruitment ongoing
Phase III
DANUBE
Stage IV, 1st-line cisplatin chemotherapy- eligible/ineligible bladder cancer
SoC chemotherapy or Imfinzi or Imfinzi + treme
FPCD
Q4 2015
 
LPCD
Q1 2017
Primary endpoints not met
Phase III
NILE
Stage IV, 1st-line cisplatin chemotherapy- eligible bladder cancer
SoC chemotherapy or SoC + Imfinzi or SoC + Imfinzi + treme
FPCD
Q4 2018
 
First data anticipated
2021+
 
Recruitment
Ongoing
Phase III
KESTREL
Stage IV, 1st-line HNSCC[50]
SoC or Imfinzi or Imfinzi + treme
FPCD
Q4 2015
 
LPCD
Q1 2017
 
First data
anticipated
2021
Recruitment completed
Phase III
HIMALAYA
Stage IV, 1st-line unresectable HCC
Sorafenib or Imfinzi or Imfinzi + treme
FPCD
Q4 2017
 
LPCD
Q4 2019
 
First data
anticipated
H2 2020
Recruitment
completed
 
Orphan Drug Designation (US)[51]
Phase III
TOPAZ-1
Stage IV, 1st-line biliary-tract cancer
Gemcitabine and cisplatin SoC chemotherapy or SoC + Imfinzi
FPCD
Q2 2019
 
First data anticipated
2021+
Recruitment ongoing
 
The Phase III KESTREL trial's final analysis plan for Imfinzi with and without tremelimumab in 1st-line HNSCC is being optimised following learnings from the EAGLE trial in the 2nd-line HNSCC setting and learned regulatory insights; as such the data readout is now expected in 2021.
 
c)  Lynparza (multiple cancers)
During the period, Lynparza was added to the US National Comprehensive Cancer Network's guidelines, in combination with bevacizumab in ovarian cancer patients who had previously been treated with bevacizumab.
 
In March 2020, the Company announced that Lynparza had been granted orphan designation in Japan for the maintenance treatment of germline BRCAm curatively unresectable pancreatic cancer. The Japan Ministry of Health, Labour and Welfare (MHLW) grants the designation to medicines intended for the treatment of diseases that affect fewer than 50,000 patients in Japan and for which there is a high unmet medical need. During the period, the Company made a regulatory submission in Japan for Lynparza in prostate cancer, based on data from the Phase III PROfound trial.
 
In April 2020, AstraZeneca announced further positive results from the Phase III PROfound trial of Lynparza in men with metastatic castration-resistant prostate cancer who have a homologous recombination repair gene mutation (HRRm) and have progressed on prior treatment with new hormonal-agent treatments, such as enzalutamide and abiraterone.
 
Table 25: Key Lynparza trials
 
 
Trial
Population
Design
Timeline
Status
Phase III
OlympiA
Adjuvant BRCAm breast cancer
SoC placebo or Lynparza
 
FPCD
Q2 2014
 
LPCD
Q2 2019
 
First data anticipated
2021
Recruitment completed
 
Phase III
PROfound
Metastatic castration-resistant 2nd-line+ HRRm
 prostate cancer
SoC (abiraterone or enzalutamide) or Lynparza
FPCD
Q2 2017
 
LPCD
Q4 2018
Primary endpoint met
 
Priority Review (US)
Phase III
PAOLA-1[52]
Advanced 1st-line
ovarian cancer
Bevacizumab maintenance or
bevacizumab +
Lynparza maintenance
FPCD
Q2 2015
 
LPCD
Q2 2018
Primary endpoint met
 
Priority Review (US)
Phase III
GY004[53]
Recurrent platinum-sensitive ovarian cancer
SoC chemotherapy or Lynparza or cediranib + Lynparza
FPCD
Q1 2016
 
LPCD
Q4 2017
Primary endpoint not met
Phase II/III
GY00553
Recurrent platinum-resistant/refractory ovarian cancer
SoC chemotherapy or cediranib or cediranib + Lynparza
FPCD
Q2 2016
(Phase II)
 
FPCD
Q1 2019
(Phase III)
 
First data
anticipated
2021+
Recruitment ongoing
(Phase III component)
Phase III
DuO-O
Advanced 1st-line
ovarian cancer
Chemotherapy +
bevacizumab or
chemotherapy +
bevacizumab +
Imfinzi +/-
Lynparza maintenance
FPCD
Q1 2019
 
First data
anticipated
2021+
Recruitment
ongoing
Phase III
PROpel
Stage IV, advanced, castration-resistant prostate cancer
Abiraterone or
abiraterone +
Lynparza
FPCD
Q4 2018
 
First data
anticipated
2021
Recruitment ongoing
 
Enhertu (breast and other cancers)
During the period, Daiichi Sankyo announced that Enhertu had been approved by Japan's MHLW for the treatment of patients with HER2+ unresectable or metastatic breast cancer, following chemotherapy. Approval of Enhertu was based on the results of the pivotal Phase II DESTINY-Breast01 trial of Enhertu monotherapy in HER2+ metastatic breast cancer patients.
 
Table 26: Key Enhertu trials
 
 
Trial
Population
Design
Timeline
Status
Phase II
DESTINY-Breast01
Stage IV, HER2+ (IHC[54] 3+ and IHC 2+/ISH[55]+) breast cancer post trastuzumab emtansine
Enhertu
(single arm)
FPCD
Q4 2017
 
LPCD
Q4 2018
Primary objective met
 
Breakthrough Therapy Designation (US)
 
Approval (JP), accelerated approval (US)
Phase III
DESTINY-Breast02
Stage IV, HER2+ (IHC 3+ and IHC 2+/ISH+) breast cancer post trastuzumab emtansine
SoC chemotherapy or Enhertu
FPCD
Q4 2018
 
First data anticipated
2021
Recruitment ongoing
Phase III
DESTINY-Breast03
Stage IV, HER2+ (IHC 3+ and IHC 2+/ISH+) breast cancer
Trastuzumab emtansine or Enhertu
FPCD
Q4 2018
 
First data anticipated
2021
Recruitment ongoing
Phase III
DESTINY-Breast04
Stage IV, HER2-low (IHC 1+/2+) breast cancer
SoC chemotherapy or Enhertu
FPCD
Q4 2018
 
First data anticipated
2021
Recruitment ongoing
Phase II
DESTINY-Gastric01
Stage IV, HER2+ (IHC 3+ and IHC 2+/ISH+) gastric cancer
SoC chemotherapy or Enhertu
FPCD
Q4 2017
 
LPCD
Q2 2019
Primary endpoint met
 
Koselugo (NF1)
During the period, the Company announced that the US FDA has approved the MEK 1/2 inhibitor, Koselugo (formerly selumetinib) for the treatment of paediatric patients aged two years and older who suffer from NF1 and symptomatic, inoperable plexiform neurofibromas (PNs). The approval was based on positive results from the National Cancer Institute (NCI) Cancer Therapy Evaluation Program-sponsored Phase II SPRINT Stratum 1 trial, coordinated by the NCI's Center for Cancer Research, Pediatric Oncology Branch. This was the first regulatory approval anywhere in the world of a medicine for the treatment of NF1 PNs.
 
During the period, Koselugo received a regulatory submission acceptance in the EU for the treatment of NF1.
 
Cediranib
In March 2020, the Company announced high-level results from the Phase III GY004 trial, led by NRG Oncology and sponsored by the US NCI, that examined the efficacy and safety of the potential new medicine cediranib when added to Lynparza versus platinum-based chemotherapy in patients with platinum-sensitive relapsed ovarian cancer. The trial did not meet the primary endpoint, in the intention-to-treat population, of a statistically significant improvement in PFS. Cediranib is an oral vascular endothelial growth factor receptor inhibitor, which blocks the growth of blood vessels supporting tumour growth.
 
 
CVRM
 
a)   Farxiga (heart failure)
In March 2020, the Company announced that the DAPA-CKD Phase III trial for Farxiga in patients with CKD would be stopped early, following a recommendation from an IDMC, based on its determination of overwhelming efficacy. The decision followed a routine assessment of efficacy and safety. The Company anticipates presentation of the data at a forthcoming medical meeting.
 
During the period, the Company decided not to pursue the application for Farxiga in type-1 diabetes in the US. This followed a complete response letter received in 2019. Forxiga is currently approved for the treatment of type-1 diabetes in the EU and Japan.
 
Table 27: Key large CVRM outcomes trials
 
 
Trial
Population
Design
Primary endpoint(s)
Timeline
Status
Farxiga
 
Phase III
DAPA-HF
c.4,500 patients with HF and reduced ejection fraction, with and without T2D
 
Arm 1: Farxiga 10mg or 5 mg QD[56] + SoC
 
Arm 2: placebo + SoC
Time to first occurrence of CV death or hospitalisation due to HF or an urgent HF visit
FPCD
Q1 2017
 
 LPCD
Q4 2018
Primary endpoint met
 
Fast Track designation (US)
Phase III
DELIVER
c.4,700 patients with HF and preserved ejection fraction, with and without T2D
 
Arm 1: Farxiga 10mg QD
 
Arm 2: placebo
Time to first occurrence of CV death or worsening HF
FPCD
Q4 2018
 
First data anticipated 2021+
 
Recruitment ongoing
 
Fast Track designation (US)
Phase III
DAPA-CKD
c.4,000 patients with CKD, with and without T2D
Arm 1: Farxiga 10mg or 5mg QD
 
Arm 2: placebo
Time to first occurrence of ≥ 50% sustained decline in eGFR[57] or reaching ESRD[58] or CV death or renal death
 
FPCD
Q1 2017
 
LPCD
Q1 2020
Trial stopped early based on recommendation from an IDMC
 
Fast Track designation (US)
Brilinta
 
Phase III THEMIS
c.19,000 patients with T2D and CAD without a history of MI or stroke
Arm 1: Brilinta 60mg BID[59]
 
Arm 2: placebo BID on a background of aspirin if not contra-indicated[60] or not tolerated
Composite of CV death, non-fatal MI and non-fatal stroke
FPCD
Q1 2014
 
LPCD
Q2 2016
Primary endpoint met
Phase III
THALES
c.11,000 patients with acute ischaemic stroke or transient ischaemic attack
Arm 1: Brilinta 90mg BID
 
Arm 2: placebo BID on a background of aspirin if not contra-indicated or not tolerated
Prevention of the composite of subsequent stroke and death at 30 days
FPCD
Q1 2018
 
LPCD
Q4 2019
Primary endpoint met
 
b)   Lokelma (hyperkalaemia)
In April 2020, the US FDA approved a label update for Lokelma to include a dosing regimen specifically to treat hyperkalaemia (elevated levels of potassium in the blood) in patients with end-stage renal disease on chronic haemodialysis. The approval by the agency was based on positive results from the Phase IIIb DIALIZE trial.
 
Similarly, during the period, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion on a dosing and administration label update for Lokelma to include patients with hyperkalaemia on stable haemodialysis. The recommendation was also based on data from the Phase IIIb DIALIZE trial, which showed that 41% of patients receiving Lokelma maintained pre-dialysis potassium levels on at least three out of four dialysis treatments after the long interdialytic interval and did not require urgent rescue therapy. This compared with 1.0% of patients receiving placebo, making it a statistically significant and clinically meaningful improvement. The safety profile of Lokelma observed in DIALIZE was consistent with previous trials.
 
In March 2020, Lokelma was approved in Japan for the treatment of patients with hyperkalaemia. The approval by the MHLW was based on positive results from stand-alone trials in Japan and the global clinical-trial programme. Lokelma is approved for the treatment of hyperkalaemia in the US, EU, Canada, Hong Kong, China, Russia and most recently, Japan.
 
c)   Roxadustat (anaemia)
During the period, AstraZeneca accomplished a number of regulatory submissions for roxadustat in rest-of-world countries, including Brazil, Chile, India, Mexico, Philippines, South Korea and Taiwan. In addition, a regulatory submission was made to the ACSS consortium for Australia, Canada and Singapore. FibroGen and Astellas are responsible for European regulatory submissions, including Switzerland.
 
 
Respiratory & Immunology
AstraZeneca has taken the opportunity to rename its Respiratory therapy area Respiratory & Immunology. With common pathways and underlying disease drivers across respiratory and immunology, AstraZeneca is following the science from chronic lung diseases to immunology-driven disease areas.
 
Fasenra (eosinophil-driven diseases)
During the period, the Company announced three new trials for Fasenra in skin diseases, adding to the five trials already underway for the medicine in eosinophil-driven diseases (EDDs) beyond severe asthma. In EDD, immune-system dysfunction causes eosinophil recruitment and activation of eosinophils (a type of white blood cell), leading to chronic local and/or systemic inflammation. The three new trials for Fasenra in skin diseases include two Phase II trials to assess the potential of the medicine as a treatment for atopic dermatitis and chronic spontaneous urticaria, as well as a Phase III trial in bullous pemphigoid (BP).
 
Table 28: Key Fasenra lifecycle management trials
 
 
Trial
Population
Design
Primary endpoint(s)
Timeline
Status
Phase III OSTRO
Patients (aged 18-75 years) with severe bilateral nasal polyposis; symptomatic, despite SoC
Placebo or Fasenra 30mg Q8W SC
Nasal-polyposis burden and reported nasal blockage
FPCD
Q1 2018
 
LPCD
Q2 2019
 
Data anticipated
H2 2020
Recruitment completed
Phase III RESOLUTE
Patients with moderate to very severe COPD with a history of frequent COPD exacerbations and elevated peripheral blood eosinophils
Placebo or Fasenra 100mg Q8W SC
Annualised rate of moderate or severe COPD exacerbations
FPCD
Q4 2019
 
Data anticipated 2021+
Recruitment ongoing
Phase III
MANDARA
Eosinophilic granulomatosis with polyangiitis
Fasenra 30mg or
mepolizumab 3x100mg Q4W
Proportion of patients who achieve remission, defined as a score[61] =0 and an OCS dose ≤4 mg/day at weeks 36 and 48
FPCD
Q4 2019
 
Data anticipated
2021+
Recruitment ongoing
 
Orphan Drug Designation (US)
Phase III
NATRON
HES[62]
Placebo or Fasenra 30mg Q4W SC
Time to HES worsening flare or any cytotoxic and/or immuno-suppressive therapy increase or hospitalisation
FPCD
Q4 2019
 
Data anticipated 2021+
Recruitment ongoing
 
Orphan Drug Designation (US)
Phase III
MESSINA
Eosinophilic oesophagitis
Placebo or Fasenra 30mg Q4W SC
Proportion of patients with a histologic response
 
Changes from baseline in dysphagia PRO[63]
Data anticipated 2021+
Recruitment ongoing
 
Orphan Drug Designation (US)
Phase III
FJORD
BP
Placebo or Fasenra 30mg Q4W SC
Proportion of patients with partial or
complete remission of BP whilst off OCS for ≥2 months
at Week 36
Data anticipated 2021+
Initiating
 
 
 

For more details on the development pipeline, including anticipated timelines for regulatory submission/acceptances, please refer to the latest Clinical Trials Appendix available on astrazeneca.com.
 

 
 
Interim Financial Statements
 
Table 29: Condensed consolidated statement of comprehensive income - Q1 2020
 
 
For the quarter ended 31 March
2020
2019
$m
$m
Total Revenue
6,354
5,491
Product Sales
6,311
5,465
Collaboration Revenue
43
26
Cost of Sales
(1,420)
(1,129)
Gross Profit
4,934
4,362
Distribution costs
(87)
(78)
Research and development expense
(1,388)
(1,266)
Selling, general and administrative costs
(2,719)
(2,514)
Other operating income and expense
480
593
Operating Profit
1,220
1,097
Finance income
51
55
Finance expense
(332)
(367)
Share of after-tax losses in associates and joint ventures
(4)
(27)
Profit Before Tax
935
758
Taxation
(185)
(195)
Profit for the period
750
563
Other comprehensive income
 
 
Items that will not be reclassified to profit or loss
 
 
Remeasurement of the defined benefit pension liability
440
10
Net gains on equity investments measured at fair value through other comprehensive income
171
120
Fair value movements related to own credit risk on bonds designated as fair value through profit or loss
21
(1)
Tax on items that will not be reclassified to profit or loss
(66)
(43)
 
566
86
Items that may be reclassified subsequently to profit or loss
 
 
Foreign exchange arising on consolidation
(608)
53
Foreign exchange arising on designating borrowings in net investment hedges
(380)
(180)
Fair value movements on cash flow hedges
(187)
(54)
Fair value movements on cash flow hedges transferred to profit or loss
45
47
Fair value movements on derivatives designated in net investment hedges
60
3
Costs of hedging
(5)
(6)
Tax on items that may be reclassified subsequently to profit or loss
73
23
 
(1,002)
(114)
Other comprehensive loss for the period, net of tax
(436)
(28)
Total comprehensive income for the period
314
535
Profit attributable to:
 
 
Owners of the Parent
780
593
Non-controlling interests
(30)
(30)
 
750
563
Total comprehensive income attributable to:
 
 
Owners of the Parent
345
565
Non-controlling interests
(31)
(30)
 
314
535
Basic earnings per $0.25 Ordinary Share
 $0.59
 $0.47
Diluted earnings per $0.25 Ordinary Share
 $0.59
 $0.47
Weighted average number of Ordinary Shares in issue (millions)
1,312
1,267
Diluted weighted average number of Ordinary Shares in issue (millions)
1,313
1,268
 
Table 30: Condensed consolidated statement of financial position
 
 
 
At 31 Mar 2020
At 31 Dec 2019
At 31 Mar 2019
$m
$m
$m
Assets
 
 
 
Non-current assets
 
 
 
Property, plant and equipment
7,347
7,688
7,446
Right-of-use assets
644
647
707
Goodwill
11,569
11,668
11,674
Intangible assets
19,718
20,833
22,852
Investments in associates and joint ventures
44
58
76
Other investments
1,476
1,401
1,530
Derivative financial instruments
104
61
94
Other receivables
527
740
496
Deferred tax assets
2,960
2,718
2,531
 
44,389
45,814
47,406
Current assets
 
 
 
Inventories
3,123
3,193
3,050
Trade and other receivables
5,080
5,761
5,289
Other investments
752
849
822
Derivative financial instruments
61
36
234
Income tax receivable
262
285
118
Cash and cash equivalents
3,413
5,369
4,136
Assets held for sale
131
70
-
 
12,822
15,563
13,649
Total assets
57,211
61,377
61,055
Liabilities
 
 
 
Current liabilities
 
 
 
Interest-bearing loans and borrowings
(2,289)
(1,822)
(3,544)
Lease liabilities
(181)
(188)
(175)
Trade and other payables
(12,633)
(13,987)
(13,102)
Derivative financial instruments
(31)
(36)
(28)
Provisions
(649)
(723)
(397)
Income tax payable
(1,260)
(1,361)
(1,010)
 
(17,043)
(18,117)
(18,256)
Non-current liabilities
 
 
 
Interest-bearing loans and borrowings
(15,634)
(15,730)
(17,320)
Lease liabilities
(472)
(487)
(539)
Derivative financial instruments
(188)
(18)
(5)
Deferred tax liabilities
(2,501)
(2,490)
(3,267)
Retirement benefit obligations
(2,129)
(2,807)
(2,385)
Provisions
(807)
(841)
(379)
Other payables
(6,221)
(6,291)
(6,875)
 
(27,952)
(28,664)
(30,770)
Total liabilities
(44,995)
(46,781)
(49,026)
Net assets
12,216
14,596
12,029
Equity
 
 
 
Capital and reserves attributable to equity holders of the Parent
 
 
 
Share capital
328
328
317
Share premium account
7,946
7,941
4,438
Other reserves
2,056
2,046
2,046
Retained earnings
448
2,812
3,682
 
10,778
13,127
10,483
Non-controlling interests
1,438
1,469
1,546
Total equity
12,216
14,596
12,029
 
Table 31: Condensed consolidated statement of changes in equity
 
 
 
Share capital
Share premium account
Other reserves
Retained earnings
Total attributable to owners of the parent
Non-controlling interests
Total equity
 
$m
$m
$m
$m
$m
$m
$m
At 1 Jan 2019
317
4,427
2,041
5,683
12,468
1,576
14,044
 
 
 
 
 
 
 
 
Adoption of new accounting standards
-
-
-
54
54
-
54
Profit for the period
-
-
-
593
593
(30)
563
Other comprehensive loss
-
-
-
(28)
(28)
-
(28)
Transfer to other reserves
-
-
5
(5)
-
-
-
Transactions with owners:
 
 
 
 
 
 
 
Dividends
-
-
-
(2,403)
(2,403)
-
(2,403)
Issue of Ordinary Shares
-
11
-
-
11
-
11
Share-based payments charge for the period
-
-
-
53
53
-
53
Settlement of share plan awards
-
-
-
(265)
(265)
-
(265)
 
 
 
 
 
 
 
 
Net movement
-
11
5
(2,001)
(1,985)
(30)
(2,015)
 
 
 
 
 
 
 
 
At 31 Mar 2019
317
4,438
2,046
3,682
10,483
1,546
12,029
 
 
 
 
 
 
 
 
At 1 Jan 2020
328
7,941
2,046
2,812
13,127
1,469
14,596
 
 
 
 
 
 
 
 
Profit for the period
-
-
-
780
780
(30)
750
Other comprehensive loss
-
-
-
(435)
(435)
(1)
(436)
Transfer to other reserves
-
-
10
(10)
-
-
-
Transactions with owners:
 
 
 
 
 
 
-
Dividends
-
-
-
(2,489)
(2,489)
-
(2,489)
Issue of Ordinary Shares
-
5
-
-
5
-
5
Share-based payments charge for the period
-
-
-
53
53
-
53
Settlement of share plan awards
-
-
-
(263)
(263)
-
(263)
Net movement
-
5
10
(2,364)
(2,349)
(31)
(2,380)
 
 
 
 
 
 
 
 
At 31 Mar 2020
328
7,946
2,056
448
10,778
1,438
12,216
 
Table 32: Condensed consolidated statement of cash flows
 
 
For the quarter ended 31 March
2020
2019
$m
$m
Cash flows from operating activities
 
 
Profit Before Tax
935
758
Finance income and expense
281
312
Share of after-tax losses of associates and joint ventures
4
27
Depreciation, amortisation and impairment
841
676
Increase in working capital and short-term provisions
(445)
(710)
Gains on disposal of intangible assets
(358)
(512)
Fair value movements on contingent consideration arising from business combinations
(33)
8
Non-cash and other movements
(429)
(404)
Cash generated from operations
796
155
Interest paid
(180)
(208)
Tax paid
(477)
(334)
Net cash inflow/(outflow) from operating activities
139
(387)
Cash flows from investing activities
 
 
Payment of contingent consideration from business combinations
(167)
(219)
Purchase of property, plant and equipment
(186)
(174)
Disposal of property, plant and equipment
-
28
Purchase of intangible assets
(190)
(586)
Disposal of intangible assets
365
1,071
Movement in profit-participation liability
-
150
Purchase of non-current asset investments
(115)
(3)
Disposal of non-current asset investments
184
17
Movement in short-term investments, fixed deposits and other investing instruments
98
20
Payments to associates and joint ventures
(8)
(12)
Interest received
28
36
Net cash inflow from investing activities
9
328
Net cash inflow/(outflow) before financing activities
148
(59)
Cash flows from financing activities
 
 
Proceeds from issue of share capital
6
11
Issue of loans
-
500
Dividends paid
(2,398)
(2,432)
Hedge contracts relating to dividend payments
(93)
26
Repayment of obligations under leases
(53)
(42)
Movement in short-term borrowings
176
1,239
Net cash outflow from financing activities
(2,362)
(698)
Net decrease in cash and cash equivalents in the period
(2,214)
(757)
Cash and cash equivalents at the beginning of the period
5,223
4,671
Exchange rate effects
(32)
12
Cash and cash equivalents at the end of the period
2,977
3,926
Cash and cash equivalents consist of:
 
 
Cash and cash equivalents
3,413
4,136
Overdrafts
(436)
(210)
 
2,977
3,926
 
Notes to the Interim Financial Statements
 
 
1)    Basis of preparation and accounting policies
These unaudited Interim Financial Statements for the three months ended 31 March 2020 have been prepared in accordance with IAS 34 'Interim Financial Reporting' as issued by the International Accounting Standards Board (IASB) and as adopted by the EU. The UK has yet to announce its post-Brexit IFRS-adoption authority and, for the current time, will follow the EU approval process.
 
The unaudited Interim Financial Statements for the three months ended 31 March 2020 were approved by the Board of Directors for release on 29 April 2020.
 
The annual financial statements of the Group are prepared in accordance with IFRSs as issued by the IASB and adopted by the EU. Except as noted below, the Interim Financial Statements have been prepared applying the accounting policies that were applied in the preparation of the Group's published consolidated financial statements for the year ended 31 December 2019.
 
IFRS 3
An amendment to IFRS 3 'Business Combinations' relating to the definition of a business was endorsed by the EU in April 2020 with an effective date of 1 January 2020. The change in definition of a business within IFRS 3 introduces an optional concentration test to perform a simplified assessment of whether an acquired set of activities and assets is or is not a business on a transaction by transaction basis. This change is expected to provide more reliable and comparable information about certain transactions as it provides more consistency in accounting in the pharmaceutical industry for substantially similar transactions for which, under the previous definition, may have been accounted in different ways, despite limited differences in substance. The Group has adopted this amendment from the effective date.
 
IFRS 9, IAS 39 and IFRS 7
Amendments to IFRS 9 'Financial Instruments', IAS 39 'Financial Instruments: Recognition and Measurement' and IFRS 7 'Financial Instruments: Disclosures' relating to interbank offered rate (IBOR) reform were endorsed by the EU in January 2020. The Group adopted the amendments in the year ended 31 December 2019. The replacement of benchmark interest rates such as the London Inter-bank Offered Rate (IBOR) and other IBORs is a priority for global regulators. The amendments provide relief from applying specific hedge-accounting requirements to hedge relationships directly affected by IBOR reform and have the effect that IBOR reform should generally not cause hedge accounting to terminate. There is no financial impact from the early adoption of these amendments.
 
The Group has one IFRS 9 designated hedge relationship that is potentially impacted by IBOR reform, namely a €300m cross-currency interest-rate swap in a fair-value hedge relationship with €300m of a €750m 0.875% 2021 non-callable bond. This swap references three-month USD LIBOR and uncertainty arising from the Group's exposure to IBOR reform will cease when the swap matures in 2021. The implications on the wider business of IBOR reform will be assessed this year.
 
COVID-19
AstraZeneca has assessed the impact of the uncertainty presented by the COVID-19 pandemic on the Interim Financial Statements comprising the financial results to 31 March 2020 and the financial position as at 31 March 2020, specifically considering the impact on key judgements and significant estimates as detailed on page 173 of the Annual Report and 20-F Information 2019 along with a several other areas of increased risk.
 
A detailed assessment has been performed, focussing on the following areas:
 
-     recoverable value of goodwill, intangible assets and property, plant and equipment
-     impact on key assumptions used to estimate contingent consideration liabilities
-     key assumptions used in estimating the Group's defined-benefit pension obligations;
-     basis for estimating clinical-trial accruals
-     key assumptions used in estimating rebates, chargebacks and returns for US Product Sales
-     valuations of unlisted equity investments
-     expected credit losses associated with changes in credit risk relating to trade and other receivables
-     net realisable value of inventories
-     fair value of certain financial instruments
-     recoverability of deferred tax assets
 
Given the significant volatility experienced in the financial markets, the assumptions used to estimate the Group's material defined-benefit pension obligations were updated and resulted in a $678m reduction in the Group's overall defined-benefit pension deficit. This reduction primarily reflected declines in liability valuations from lower-inflation expectations and higher discount rates (due to rising long term AA corporate bond yields) and more than offset declines in asset values, which held up relatively well in difficult market conditions. In the UK, £79m of deficit-recovery contributions were also paid. The sensitivity of the Group's main defined-benefit liability valuations to changes in assumptions is set out on page 207 of the Annual Report and Form 20-F Information 2019.
 
No further material accounting impacts relating to the areas assessed above were recognised during the three-month period ending 31 March 2020.
 
The Group will continue to monitor these areas of increased judgement and risk for material changes.
 
Going concern
The Group has considerable financial resources available. As at 31 March 2020, the Group had $8.3bn in financial resources (cash and cash-equivalent balances of $3.4bn, $0.8bn of liquid fixed income securities and undrawn committed bank facilities of $4.1bn, of which $3.4bn is available until April 2022, $0.5bn is available until November 2020 (extendable to November 2021) and $0.2bn is available until December 2020, with only $2.5bn of borrowings due within one year). The Group's revenues are largely derived from sales of medicines which are covered by patents which provide a relatively high level of resilience and predictability to cash inflows, although government price interventions in response to budgetary constraints are expected to continue to adversely affect revenues in many of the mature markets. The Group, however, anticipates new revenue streams from both recently launched medicines and those in development, and the Group has a wide diversity of customers and suppliers across different geographic areas. Consequently, the Directors believe that, overall, the Group is well placed to manage its business risks successfully. In the current environment, the Directors have also considered the impact of a range of possible future COVID-19 related scenarios and believe the Group retains sufficient liquidity to continue to operate.
 
Based on the above paragraph, the going-concern basis has been adopted in these Interim Financial Statements.
 
Legal proceedings
The information contained in Note 5 updates the disclosures concerning legal proceedings and contingent liabilities in the Group's Annual Report and Form 20-F Information 2019.
 
Financial information
The comparative figures for the financial year ended 31 December 2019 are not the Group's statutory accounts for that financial year. Those accounts have been reported on by the Group's auditors and will be delivered to the registrar of companies; their report was (i) unqualified, (ii) did not include a reference to any matters to which the auditors drew attention by way of emphasis without qualifying their report, and (iii) did not contain a statement under section 498(2) or (3) of the Companies Act 2006.
 
2)    Intangible assets
In accordance with IAS 36 'Impairment of Assets', reviews for triggers at an individual asset or cash-generating-unit level have been conducted. This has resulted in a total impairment charge of $117m being recorded during the three months ended 31 March 2020, of which $102m is in relation to Bydureon (revised carrying amount of $627m). The impairment was driven by an overall reduction in forecast Total Revenue over the remaining asset life, reflecting expectations of returns from promotional activities, including a level of anticipated impact resulting from the restrictions in place due to the COVID-19 pandemic. If Total Revenue projections for Bydureon were to decline by a further 5% over the forecast period, it would result in a further impairment charge of c.$50m.
 
3)    Net Debt
The table below provides an analysis of Net Debt and a reconciliation of Net Cash Flow to the movement in Net Debt. The Group monitors Net Debt as part of its capital-management policy as described in Note 27 of the Annual Report and Form 20-F Information 2019. Net Debt is a non-GAAP financial measure.
 
Table 33: Net Debt
 
 
 
At 1 Jan 2020
Cash flow
Non-cash & other
Exchange movements
At 31 Mar 2020
$m
$m
$m
$m
$m
Non-current instalments of loans
(15,730)
-
7
89
(15,634)
Non-current instalments of leases
(487)
-
-
15
(472)
 
 
 
 
 
 
Total long-term debt
(16,217)
-
7
104
(16,106)
 
 
 
 
 
 
Current instalments of loans
(1,597)
-
(1)
-
(1,598)
Current instalments of leases
(188)
58
(56)
5
(181)
Commercial paper
-
(85)
-
-
(85)
Bank collateral
(71)
(93)
-
-
(164)
Other short-term borrowings excluding overdrafts
(8)
2
-
-
(6)
Overdraft
(146)
(297)
-
7
(436)
 
 
 
 
 
 
Total current debt
(2,010)
(415)
(57)
12
(2,470)
 
 
 
 
 
 
Gross borrowings
(18,227)
(415)
(50)
116
(18,576)
 
 
 
 
 
 
Net derivative financial instruments
43
93
(190)
-
(54)
 
 
 
 
 
 
Net borrowings
(18,184)
(322)
(240)
116
(18,630)
 
 
 
 
 
 
Cash and cash equivalents
5,369
(1,917)
-
(39)
3,413
Other investments - current
849
(98)
6
(5)
752
Other investments - non-current
62
-
(10)
-
52
Cash and investments
6,280
(2,015)
(4)
(44)
4,217
 
 
 
 
 
 
Net Debt
(11,904)
(2,337)
(244)
72
(14,413)
 
Non-cash movements in the period include fair-value adjustments under IFRS 9.
 
Other investments - non-current are included within the balance of $1,476m (31 December 2019: $1,401m) in the Condensed consolidated statement of financial position. The equivalent GAAP measure to net debt is 'liabilities arising from financing activities' which excludes the amounts for cash and overdrafts, other investments and non-financing derivatives shown above and includes the Acerta Pharma put-option liability of $2,182m (31 December 2019: $2,146m) shown in non-current other payables.
 
4)    Financial instruments
As detailed in the Group's most recent annual financial statements, the principal financial instruments consist of derivative financial instruments, other investments, trade and other receivables, cash and cash equivalents, trade and other payables, leases and interest-bearing loans and borrowings. There have been no changes of significance to the categorisation or fair-value hierarchy classification of our financial instruments from those detailed in the Notes to the Group Financial Statements in the Annual Report and Form 20-F Information 2019.
 
The Group holds certain equity investments that are categorised as Level 3 in the fair-value hierarchy and for which fair-value gains of $6m have been recognised in the quarter ended 31 March 2020. These are presented in Net gains on equity investments measured at fair value through other comprehensive income in the Condensed consolidated statement of comprehensive income.
 
Financial instruments measured at fair value include $2,228m of other investments, $2,035m held in money market funds, $327m of loans designated at fair value through profit or loss, $332m of loans designated in a fair value hedge relationship and ($54m) of derivatives as at 31 March 2020. The total fair value of interest-bearing loans and borrowings at 31 March 2020, which have a carrying value of $18,576m in the Condensed consolidated statement of financial position, was $20,929m. Contingent consideration liabilities arising on business combinations have been classified under Level 3 in the fair-value hierarchy and movements in fair value are shown below:
 
Table 34: Financial instruments
 
 
 
2020
 
2019
Diabetes alliance
Other
Total
Total
$m
$m
$m
$m
At 1 January
3,300
839
4,139
5,106
Settlements
(124)
(43)
(167)
(219)
Revaluations
(22)
(11)
(33)
8
Discount unwind
57
16
73
90
 
 
 
 
 
At 31 March
3,211
801
4,012
4,985
 
Contingent consideration arising from business combinations is fair-valued using decision-tree analysis, with key inputs including the probability of success, consideration of potential delays and the expected levels of future revenues.
 
The contingent consideration balance relating to BMS's share of the global diabetes alliance of $3,211m (31 December 2019: $3,300m) would increase/decline by $321m with an increase/decline in sales of 10%, as compared with the current estimates.
 
Included within the BMS contingent consideration liability includes estimates of royalties payable in relation to Bydureon. The revised Total Revenue projections for Bydureon have also resulted in a $22m reduction in the contingent consideration balance as at 31 March 2020. A further 5% reduction in Bydureon Total Revenue would result in an additional $11m reduction.
 
5)    Legal proceedings and contingent liabilities
AstraZeneca is involved in various legal proceedings considered typical to its business, including litigation and investigations relating to product liability, commercial disputes, infringement of intellectual property rights, the validity of certain patents, anti-trust law and sales and marketing practices. The matters discussed below constitute the more significant developments since publication of the disclosures concerning legal proceedings in the Company's Annual Report and Form 20-F Information 2019 (the Disclosures). Unless noted otherwise below or in the Disclosures, no provisions have been established in respect of the claims discussed below.
 
As discussed in the Disclosures, for the majority of claims in which AstraZeneca is involved, it is not possible to make a reasonable estimate of the expected financial effect, if any, that will result from ultimate resolution of the proceedings. In these cases, AstraZeneca discloses information with respect only to the nature and facts of the cases, but no provision is made.
 
In cases that have been settled or adjudicated, or where quantifiable fines and penalties have been assessed and which are not subject to appeal, or where a loss is probable and we are able to make a reasonable estimate of the loss, AstraZeneca records the loss absorbed or makes a provision for its best estimate of the expected loss. The position could change over time and the estimates that the Company made, and upon which the Company have relied in calculating these provisions are inherently imprecise. There can, therefore, be no assurance that any losses that result from the outcome of any legal proceedings will not exceed the amount of the provisions that have been booked in the accounts. The major factors causing this uncertainty are described more fully in the Disclosures and herein.
 
AstraZeneca has full confidence in, and will vigorously defend and enforce, its intellectual property.
 
Matters disclosed in respect of the first quarter of 2020 and to 29 April 2020
 
Patent litigation
 
a)   Tagrisso
US patent proceedings
As disclosed in February 2020, in response to Paragraph IV notices from multiple abbreviated new drug application (ANDA) filers, AstraZeneca filed patent-infringement lawsuits in the US District Court for the District of Delaware. In its complaint, AstraZeneca alleged that a generic version of Tagrisso, if approved and marketed, would infringe a US Orange Book-listed Tagrisso patent. No trial date has been set.
 
b)   Symbicort
US patent proceedings
As previously disclosed, AstraZeneca has ANDA litigation against Mylan Pharmaceuticals Inc. (Mylan) and 3M Company (3M) in the US District Court for the Northern District of West Virginia. In the action, AstraZeneca alleges that the defendants' generic versions of Symbicort, if approved and marketed, would infringe various AstraZeneca patents. Mylan and 3M allege that their proposed generic medicines do not infringe the asserted patents and/or that the asserted patents are invalid and/or unenforceable. The trial of the Mylan and 3M matter is scheduled for October 2020.
 
c)   Movantik
US patent proceedings
In March 2020, Aether Therapeutics, Inc. filed a patent infringement lawsuit in the US District Court for the District of Delaware against AstraZeneca, Nektar Therapeutics and Daiichi Sankyo relating to Movantik.
 
 
Commercial litigation
 
Amplimmune
As disclosed in the US in June 2017, AstraZeneca was served with a lawsuit filed by the stockholders' agents for Amplimmune, Inc. (Amplimmune) in Delaware State Court that alleged, among other things, breaches of contractual obligations relating to a 2013 merger agreement between AstraZeneca and Amplimmune. Trial of the matter was held in February 2020 and post-trial oral argument is scheduled for June 2020.
 
 
Government investigations/proceedings
 
a)   Synagis
Litigation in New York
As disclosed in the US in June 2011, MedImmune received a demand from the US Attorney's Office for the Southern District of New York requesting certain documents related to the sales and marketing activities of Synagis. In July 2011, MedImmune received a similar court order to produce documents from the Office of the Attorney General for the State of New York Medicaid and Fraud Control Unit pursuant to what the government attorneys advised was a joint investigation. MedImmune has co-operated with these inquiries. In March 2017, MedImmune was served with a lawsuit filed in US District Court for the Southern District of New York by the Attorney General for the State of New York, alleging that MedImmune inappropriately provided assistance to a single specialty-care pharmacy. In September 2018, the US District Court in New York denied MedImmune's motion to dismiss the lawsuit brought by the Attorney General for the State of New York.
 
In June 2017, MedImmune was served with a lawsuit in US District Court for the Southern District of New York by a relator under the qui tam (whistle-blower) provisions of the federal and certain state False Claims Acts. The lawsuit was originally filed under seal in April 2009 and alleged that MedImmune made false claims about Synagis. In November 2017, MedImmune was served with an amended complaint in which relator set forth additional false claims' allegations relating to Synagis. In September 2018, the US District Court in New York dismissed the relator's lawsuit. In January 2019, relator appealed the decision of the US District Court in New York. In March 2020, the United States Court of Appeals for the Second Circuit affirmed the US District Court's decision dismissing the relator's lawsuit.
 
b)   Crestor
Qui tam litigation
As previously disclosed, in the US, in January and February 2014, AstraZeneca was served with lawsuits filed in the US District Court for the District of Delaware under the qui tam provisions of the federal False Claims Act and related state statutes, alleging that AstraZeneca directed certain employees to promote Crestor off-label and provided unlawful remuneration to physicians in connection with the promotion of Crestor. The Department of Justice and all US states declined to intervene in the lawsuits. In March 2019, AstraZeneca filed a motion to dismiss the complaint. In February 2020, the District Court partially granted AstraZeneca's motion to dismiss.
 
Vermont US Attorney investigation
In April 2020, AstraZeneca received a Civil Investigative Demand from the US Attorney's Office in Vermont and the Department of Justice, Civil Division, seeking documents and information relating to AstraZeneca's relationships with electronic health-record vendors. AstraZeneca intends to co-operate with this enquiry. 
 
6)    Subsequent events
In April 2020, AstraZeneca completed an agreement to sublicense its global rights to Movantik, excluding Europe, Canada and Israel, to RedHill Biopharma (RedHill) for $67.5m. A related intangible was classified as a current asset held for sale at 31 March 2020.
 
In April 2020, AstraZeneca and Circassia agreed to terminate the development and commercialisation agreement relating to Tudorza and Duaklir in the US. The agreement is expected to close in Q2 2020. Upon completion, the rights to the assets will revert to AstraZeneca in consideration for the release of amounts outstanding under a loan agreement that arose from transactions relating to the agreement. The loan was previously classified as a non-current asset and has been reclassified as a current asset at 31 March 2020.
 
In April 2020, the Company signed and closed an agreement with Taiyo Pharma Co. Ltd to divest the rights to Inderal, Tenormin, Seloken and Omepral in Japan for ¥5,900m.
 

 
 
 
7)    Product Sales year-on-year analysis[64]
 
Table 35: Product Sales year-on-year analysis - Q1 2020
 
 
 
World
Emerging Markets
US
Europe
Established RoW
$m
% change
$m
% change
$m
% change
$m
% change
$m
% change
Actual
CER
Actual
CER
Actual
Actual
CER
Actual
CER
Oncology
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tagrisso
982
56
58
280
n/m
n/m
371
43
162
62
66
169
27
26
Imfinzi
462
57
57
33
n/m
n/m
286
24
75
n/m
n/m
68
94
93
Lynparza
397
67
69
56
n/m
n/m
197
66
102
57
61
42
57
56
Calquence
88
n/m
n/m
1
n/m 
n/m
86
n/m
- 
- 
- 
1
n/m 
n/m 
Zoladex*
225
16
19
149
30
35
2
24
35
1
3
39
(10)
(9)
Faslodex*
166
(35)
(34)
48
7
10
23
(83)
64
19
22
31
7
5
Iressa*
77
(42)
(41)
62
(28)
(26)
4
(2)
5
(79)
(78)
6
(69)
(69)
Arimidex*
50
(1)
1
41
16
20
- 
- 
1
(85)
(85)
8
(14)
(15)
Casodex*
42
(12)
(10)
33
8
11
- 
- 
1
(84)
(84)
8
(37)
(37)
Others
13
(37)
(36)
8
(11)
(9)
1
- 
1
19
23
3
(60)
(61)
Total Oncology
2,502
32
34
711
45
49
970
26
446
42
46
375
18
17
BioPharmaceuticals: CVRM
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Farxiga
405
16
19
141
49
55
113
(14)
116
30
34
35
2
3
Brilinta
408
17
19
134
38
42
165
8
93
12
15
16
8
10
Bydureon
100
(30)
(29)
1
(41)
(39)
84
(28)
12
(34)
(32)
3
(46)
(44)
Onglyza
141
(8)
(6)
47
10
13
67
(14)
15
(19)
(17)
12
(10)
(10)
Byetta
20
(32)
(31)
3
n/m
n/m
11
(42)
4
(37)
(35)
2
(17)
(13)
Other diabetes
13
16
18
2
n/m
n/m
7
(9)
3
50
56
1
- 
- 
Lokelma
11
n/m 
n/m 
- 
- 
- 
10
n/m
1
n/m 
n/m 
- 
- 
- 
Roxadustat
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
Crestor*
301
(10)
(9)
192
(15)
(13)
28
9
34
(12)
(10)
47
4
4
Seloken/Toprol-XL*
177
(21)
(18)
166
(14)
(11)
4
(82)
4
(29)
(29)
3
(2)
2
Atacand*
66
33
36
49
25
29
3
33
8
n/m
n/m
6
32
36
Others
59
(18)
(17)
37
(28)
(27)
- 
- 
19
7
9
3
22
22
BioPharmaceuticals: total CVRM
1,701
(1)
1
772
3
6
492
(12)
309
9
12
128
2
3
BioPharmaceuticals: Respiratory & Immunology
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Symbicort
790
35
36
156
17
20
310
76
195
7
10
129
37
37
Pulmicort
380
(1)
- 
313
- 
1
23
(3)
26
3
6
18
(8)
(8)
Fasenra
199
54
55
6
- 
- 
120
29
46
n/m
n/m
27
53
53
Daliresp/Daxas
53
11
12
1
(8)
(4)
45
10
7
17
21
- 
- 
- 
Bevespi
12
22
22
- 
- 
- 
12
15
- 
- 
- 
-
- 
- 
Breztri
4
n/m 
n/m 
4
n/m 
n/m 
- 
- 
- 
- 
- 
-
-
-
Others
113
(11)
(10)
59
(14)
(12)
2
38
46
(15)
(13)
6
n/m
n/m
BioPharmaceuticals: total Respiratory & Immunology
1,551
21
22
539
4
6
512
48
320
12
15
180
34
34
Other medicines
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nexium
338
(7)
(6)
187
(2)
1
40
(39)
22
36
41
89
(3)
(3)
Synagis
85
61
61
5
n/m
n/m
7
(72)
73
n/m
n/m
- 
- 
- 
Losec/Prilosec
54
(30)
(28)
44
(14)
(12)
2
96
5
(74)
(74)
3
(47)
(48)
Seroquel XR/IR
36
(4)
(3)
12
(17)
(15)
13
n/m
8
(67)
(67)
3
(47)
(48)
Others
44
(8)
(7)
1
n/m
n/m
25
(9)
15
6
9
3
(82)
(82)
Total other medicines
557
(4)
(3)
249
- 
2
87
(23)
123
23
25
98
(15)
(16)
Total Product Sales
6,311
15
17
2,271
13
16
2,061
15
1,198
22
25
781
13
12
 
8)    Product Sales quarterly sequential analysis[65]
 
Table 36: Product Sales quarterly sequential analysis - Q1 2020
 
 
 
Q1 2020
 
$m
% change
Actual
CER
Oncology
 
 
 
Tagrisso
982
11
11
Imfinzi
462
9
9
Lynparza
397
13
13
Calquence
88
58
58
Zoladex*
225
15
15
Faslodex*
166
- 
- 
Iressa*
77
(3)
(4)
Arimidex*
50
(1)
(2)
Casodex*
42
(2)
(3)
Others
13
(52)
(52)
Total Oncology
2,502
10
10
BioPharmaceuticals: CVRM
 
 
 
Farxiga
405
(3)
(3)
Brilinta
408
(5)
(5)
Bydureon
100
(28)
(28)
Onglyza
141
8
8
Byetta
20
(24)
(24)
Other diabetes
13
(22)
(22)
Lokelma
11
42
42
Roxadustat
- 
- 
- 
Crestor*
301
2
1
Seloken/Toprol-XL*
177
(6)
(6)
Atacand*
66
11
12
Others
59
(21)
(22)
BioPharmaceuticals: total CVRM
1,701
(5)
(5)
BioPharmaceuticals: Respiratory & Immunology
 
 
 
Symbicort
790
11
11
Pulmicort
380
(8)
(9)
Fasenra
199
(3)
(3)
Daliresp/Daxas
53
(8)
(8)
Bevespi
12
9
9
Breztri
4
n/m
n/m
Others
113
(16)
(17)
BioPharmaceuticals: total Respiratory & Immunology
1,551
1
1
Other medicines
 
 
 
Nexium
338
(4)
(4)
Synagis
85
35
35
Losec/Prilosec
54
18
17
Seroquel XR/IR
36
(12)
(12)
Others
44
(71)
(70)
Total other medicines
557
(15)
(15)
Total Product Sales
6,311
1
1
 
9)    Product Sales quarterly sequential analysis - FY 2019[66]
 
Table 37: Product Sales quarterly sequential analysis - FY 2019
 
 
 
Q1 2019
Q2 2019
Q3 2019
Q4 2019
$m
% change
$m
% change
$m
% change
$m
% change
Actual
CER
Actual
CER
Actual
CER
Actual
CER
Oncology
 
 
 
 
 
 
 
 
 
 
 
 
Tagrisso
630
6
6
784
24
25
891
14
13
884
(1)
- 
Imfinzi
295
13
13
338
15
15
412
22
22
424
3
4
Lynparza
237
13
13
283
19
20
327
16
15
351
7
8
Calquence
29
21
23
35
21
19
44
27
27
56
25
25
Faslodex*
254
(6)
(6)
267
5
6
205
(23)
(23)
166
(20)
(19)
Zoladex*
194
7
6
197
2
1
226
15
16
196
(14)
(12)
Iressa*
134
20
18
118
(12)
(11)
91
(23)
(22)
80
(13)
(12)
Arimidex*
51
11
10
60
18
17
63
5
5
51
(20)
(18)
Casodex*
48
4
3
57
19
18
52
(8)
(6)
43
(18)
(17)
Others
20
(13)
(14)
28
40
29
20
(27)
(22)
26
30
26
Total Oncology
1,892
7
6
2,167
15
15
2,334
8
8
2,274
(3)
(2)
BioPharmaceuticals: CVRM
 
 
 
 
 
 
 
 
 
 
 
 
Farxiga
349
(12)
(12)
377
8
9
398
5
5
419
5
6
Brilinta
348
(7)
(8)
389
12
12
416
7
8
428
3
3
Bydureon
142
3
3
141
(1)
-
127
(10)
(10)
139
9
10
Onglyza
153
3
3
116
(24)
(24)
127
9
11
131
3
4
Byetta
30
(6)
(5)
25
(17)
(16)
28
10
13
27
(2)
(4)
Other diabetes
11
(8)
(17)
11
- 
8
14
26
22
16
17
17
Lokelma
- 
n/m
n/m
2
n/m
n/m
4
n/m
n/m
8
87
74
Roxadustat
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
Crestor*
335
(5)
(6)
310
(7)
(7)
337
9
9
296
(12)
(11)
Seloken/Toprol-XL*
225
41
38
168
(25)
(25)
177
6
8
190
7
8
Atacand*
50
(14)
(15)
56
12
14
55
(1)
(1)
60
8
9
Others
71
(3)
(5)
63
(11)
(8)
65
4
2
72
13
16
BioPharmaceuticals: total CVRM
1,714
(2)
(3)
1,658
(3)
(3)
1,749
5
6
1,785
2
3
BioPharmaceuticals: Respiratory & Immunology
 
 
 
 
 
 
 
 
 
 
 
 
Symbicort
585
(8)
(8)
585
- 
1
613
5
4
712
16
17
Pulmicort
383
(2)
(2)
333
(13)
(13)
337
1
3
413
22
23
Fasenra
129
3
4
167
29
30
202
21
21
206
2
2
Daliresp/Daxas
48
(11)
(12)
56
17
18
53
(6)
(7)
58
10
10
Bevespi
10
- 
(5)
10
- 
2
10
4
8
12
8
5
Breztri
- 
- 
- 
- 
- 
- 
1
- 
- 
1
(74)
(73)
Others
128
(14)
(12)
101
(21)
(23)
102
1
(1)
135
33
38
BioPharmaceuticals: total Respiratory & Immunology
1,283
(6)
(6)
1,252
(2)
(2)
1,319
5
6
1,537
17
17
Other medicines
 
 
 
 
 
 
 
 
 
 
 
 
Nexium
363
(7)
(8)
393
8
8
374
(5)
(4)
353
(6)
(6)
Synagis
53
(79)
(79)
96
81
81
146
52
53
63
(57)
(57)
Losec/Prilosec
76
27
26
68
(11)
(10)
73
8
9
46
(38)
(38)
Seroquel XR/IR
37
(34)
(33)
32
(14)
(10)
82
n/m
n/m
40
(50)
(49)
Others
47
(65)
(64)
52
11
11
56
8
- 
151
n/m
n/m
Total other medicines
576
(35)
(36)
641
11
12
731
14
14
653
(11)
(10)
Total Product Sales
5,465
(5)
(6)
5,718
5
5
6,132
7
8
6,250
2
3
 
Table 38: Historic Collaboration Revenue
 
 
 
 
Q1 2020
Q1 2019
FY 2019
FY 2018
$m
$m
$m
$m
Initial Collaboration Revenue
Crestor (Spain)
-
-
-
61
Ongoing Collaboration Revenue
Lynparza: regulatory milestones
-
-
60
140
Lynparza: sales milestones
-
-
450
250
Lynparza/selumetinib: option payments
-
-
100
400
Crestor (Spain)
-
-
39
 
Enhertu: profit share
14
-
-
-
Roxadustat: profit share
3
-
-
-
Royalty income
17
16
62
49
 
Other Collaboration Revenue
9
10
108
141
 
Total
43
26
819
1,041
 
Table 39: Other Operating Income and Expense
 
The table below provides an analysis of Reported Other Operating Income and Expense.
 
 
Divestment/other
Q1 2020
Q1 2019
FY 2019
FY 2018
$m
$m
$m
$m
Hypertension medicines (ex-US, India and Japan)
350
-
-
-
Synagis (US)
-
515
515
-
Losec (ex-China, Japan, US and Mexico)
-
-
243
-
Seroquel and Seroquel XR (US, Canada, Europe and Russia)
-
-
213
-
Arimidex and Casodex (various countries)
-
-
181
-
Nexium (Europe) and Vimovo (ex-US)
-
-
-
728
Seroquel
-
-
-
527
Legal settlement[67]
-
-
-
346
Atacand
-
-
-
210
Anaesthetics
-
-
-
172
Alvesco, Omnaris and Zetonna
-
-
-
139
Other
130
78
389
405
Total
480
593
1,541
2,527
 
 
 
 
 
Shareholder information

 
 
Announcement of first half and second quarter results                                 30 July 2020

Announcement of year to date and third quarter results                               5 November 2020

 
Future dividends will normally be paid as follows:
First interim:
announced with half-year and second-quarter results and paid in September
Second interim:
announced with full-year and fourth-quarter results and paid in March
 
 
 
 
The record date for the first interim dividend for 2020, payable on 14 September 2020, will be 14 August 2020. The ex-dividend date will be 13 August 2020.
 
Trademarks of the AstraZeneca group of companies appear throughout this document in italics. Medical publications also appear throughout the document in italics. AstraZeneca, the AstraZeneca logotype and the AstraZeneca symbol are all trademarks of the AstraZeneca group of companies. Trademarks of companies other than AstraZeneca that appear in this document include Alvesco, Omnaris and Zetonna, trademarks of Covis Pharma; Atacand, owned by AstraZeneca or Cheplapharm (depending on geography); Duaklir, Eklira and Tudorza, trademarks of Almirall, S.A.; Enhertu, a trade mark of Daiichi Sankyo; Inderal and Tenormin, owned by AstraZeneca, Atnahs Pharma or Taiyo Pharma Co. Ltd (depending on geography); Losec and Omepral, owned by AstraZeneca, Cheplapharm  or Taiyo Pharma Co. Ltd (depending on geography); Seloken, owned by AstraZeneca or Taiyo Pharma Co. Ltd (depending on geography); Synagis, owned by Arexis AB or AbbVie Inc. (depending on geography); Vimovo, owned by AstraZeneca or Grünenthal GmbH (depending on geography).
 
Information on or accessible through AstraZeneca's websites, including astrazeneca.com, does not form part of and is not incorporated into this announcement.
 
Addresses for correspondence

 
 
 
 
 
 
Registered office
Registrar and transfer office
Swedish Central Securities Depository
US depositary
Deutsche Bank Trust Company Americas
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge
CB2 0AA
Equiniti Limited
Aspect House
Spencer Road
Lancing
West Sussex
BN99 6DA
Euroclear Sweden AB PO Box 191
SE-101 23 Stockholm
American Stock Transfer
6201 15th Avenue
Brooklyn
NY 11219
 
United Kingdom
United Kingdom
Sweden
United States
 
 
 
 
+44 (0) 20 3749 5000
0800 389 1580
+46 (0) 8 402 9000
+1 (888) 697 8018
 
+44 (0) 121 415 7033
 
+1 (718) 921 8137
 
 
 
 
 
 
Cautionary statements regarding forward-looking statements

 
In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act 1995, the Group provides the following cautionary statement:
 
This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The Forward-looking statements reflect knowledge and information available at the date of preparation of this document and AstraZeneca undertakes no obligation to update these forward-looking statements. We identify the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond our control, include, among other things:
 
-     the risk of failure or delay in delivery of pipeline or launch of new medicines
 
-     the risk of failure to meet regulatory or ethical requirements for medicine development or approval
 
-     the risk of failure to obtain, defend and enforce effective intellectual-property (IP) protection and IP challenges by third parties
 
-     the impact of competitive pressures including expiry or loss of IP rights, and generic competition
 
-     the impact of price controls and reductions
 
-     the impact of economic, regulatory and political pressures
 
-     the impact of uncertainty and volatility in relation to the UK's exit from the EU
 
-     the risk of failures or delays in the quality or execution of the Group's commercial strategies
 
-     the risk of failure to maintain supply of compliant, quality medicines
 
-     the risk of illegal trade in our products
 
-     the impact of reliance on third-party goods and services
 
-     the risk of failure in information technology, data protection or cybercrime
 
-     the risk of failure of critical processes
 
-     any expected gains from productivity initiatives are uncertain
 
-     the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce
 
-     the risk of failure to adhere to applicable laws, rules and regulations
 
-     the risk of the safety and efficacy of marketed medicines being questioned
 
-     the risk of adverse outcome of litigation and/or governmental investigations
 
-     the risk of failure to adhere to increasingly stringent anti-bribery and anti-corruption legislation
 
-     the risk of failure to achieve strategic plans or meet targets or expectations
 
-     the risk of failure in financial control or the occurrence of fraud
 
-     the risk of unexpected deterioration in the Group's financial position
 
-     the impact that the COVID-19 global pandemic may have or continue to have on these risks, on the Group's ability to continue to mitigate these risks, and on the Group's operations, financial results or financial condition
 
Nothing in this document, or any related presentation/webcast, should be construed as a profit forecast.
 
 

 
 
 
[11] Extensive stage.
[12] Small cell lung cancer.
[13] The treatment of a cancer in the advanced, metastatic setting after 2nd-line treatment (see below).
[14] Human epidermal growth factor receptor 2 positive.
[15] Neurofibromatosis type 1.
[16] Non-small cell lung cancer.
[17] Overall survival.
[18] The initial treatment of a cancer in the advanced, metastatic setting.
[19] The treatment of a cancer in the advanced, metastatic setting after the initial treatment.
[20] Chronic kidney disease.
[21] Breast cancer susceptibility genes 1/2 mutation.
[22] Type-2 diabetes.
[23] CV outcomes trial.
[24] Heart failure.
[25] Chronic obstructive pulmonary disease.
[26] Cannot be removed completely through surgery.
[27] Chronic lymphocytic leukaemia.
[28] Coronary artery disease.
[29] Painless, benign soft growths inside the nose.
[30] Systemic lupus erythematosus.
[31] HER2 immunohistochemistry 1+ or 2+ with fluorescence in situ hybridisation test result negative.
[32] A group of disorders in which the bone marrow fails to produce healthy blood cells.
[33] Substitution of threonine (T) with methionine (M) at position 790 of exon 20 mutation.
[34] Where AstraZeneca does not retain a significant ongoing interest in medicines or potential new medicines, income from divestments is reported within Other Operating Income and Expense in the Company's financial statements.
[35] As per the FY 2019 results announcement.
[36] Based on average daily spot rates in FY 2019.
[37] Based on average daily spot rates from 1 January 2020 to 31 March 2020.
[38] Other currencies include AUD, BRL, CAD, KRW and RUB.
[39] These priorities were determined through a materiality assessment conducted in 2018 with a broad range of external and internal stakeholders, respectively. Combined, they ensure the maximum possible benefit to patients, the Company, broader society and the planet. AstraZeneca's sustainability priorities align with the United Nations Sustainable Development Goals (SDG), and, in particular, SDG three for 'Good Health'.
[40] Phase II trial data, with potential for registration.
[41] Subject to regulatory approvals associated with AbbVie Inc.'s (AbbVie) proposed acquisition of Allergan plc (Allergan).
[42] First patient commenced dosing.
[43] Last patient commenced dosing.
[44] Programmed death-ligand 1, a protein that assists in the body's immune responses.
[45] Conducted by the Canadian Cancer Trials Group.
[46] Progression-free survival.
[47] Bacillus Calmette-Guerin.
[48] Hepatocellular carcinoma (liver cancer).
[49] Transarterial chemoembolisation.
[50] Head and neck squamous cell carcinoma.
[51] The US Orphan Drug Act grants special status to a medicine or potential medicine to treat a rare disease or condition upon request of a sponsor. Designation qualifies the sponsor of the medicine for various development incentives.
[52] Conducted by the ARCAGY/Groupe d'Investigateurs national des Etudes des Cancers Ovariens et du sein.
[53] Conducted by the National Cancer Institute (US).
[54] Immunohistochemistry.
[55] In situ hybridisation.
[56] Quaque die, or once a day.
[57] Estimated glomerular filtration rate.
[58] End-stage renal disease.
[59] Bis in die, or twice a day.
[60] A specific situation in which a medicine should not be used as a treatment as it may be harmful to the patient.
[61] Birmingham Vasculitis Activity Score.
[62] Hypereosinophilic syndrome.
[63] Patient-reported outcomes.
[64] The table provides an analysis of year-on-year Product Sales, with Actual and CER growth rates reflecting year-on-year growth. Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. *Denotes a legacy medicine.
[65] The table below provides an analysis of sequential quarterly Product Sales, with actual and CER growth rates reflecting quarter-on-quarter growth. Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. *Denotes a legacy medicine.
[66] The table below provides an analysis of sequential quarterly Product Sales, with actual and CER growth rates reflecting quarter-on-quarter growth. Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. *Denotes a legacy medicine.
[67] Not recorded within Core Other Operating Income and Expense.
 
 
 
 
 SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
AstraZeneca PLC
 
 
Date: 29 April 2020
 
 
By: /s/ Adrian Kemp
 
Name: Adrian Kemp
 
Title: Company Secretary